<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>peregrine_def14a-2016.htm
<DESCRIPTION>DEFINITIVE NOTICE AND PROXY STATEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">

<B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SCHEDULE 14A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Proxy Statement Pursuant to Section 14(a)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">of the Securities Exchange Act of 1934 (Amendment
No.&nbsp;&nbsp;&nbsp;&nbsp;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by the Registrant <FONT STYLE="font-family: Wingdings; font-size: 10pt">&yacute;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by a Party other than the Registrant <FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT>&#9;Preliminary
Proxy Statement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT>&#9;<B>Confidential,
for Use of the Commission Only (as permitted by Rule&nbsp;14a-6(e)(2))</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&yacute;</FONT>&#9;Definitive
Proxy Statement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT>&#9;Definitive
Additional Materials</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT>&#9;Soliciting
Material Pursuant to &sect; 240.14a-11(c) or &sect; 240.14a-12</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; border-bottom: Black 0.5pt solid; margin-bottom: 0pt; text-align: center"><B>PEREGRINE
PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Name of Registrant as Specified
In Its Charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; border-top: Black 0.5pt solid; margin-bottom: 0pt; text-align: center"><B>(Name
of Person(s) Filing Proxy Statement, if other than the Registrant)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment of Filing Fee (Check the appropriate box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Wingdings">&yacute;</FONT></P>

</TD>
    <TD COLSPAN="2">No fee required</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD COLSPAN="2">Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>(1)</TD>
    <TD>Title of each class of securities to which transaction
applies:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>(2)</TD>
    <TD>Aggregate number of securities to which transaction
applies:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>(3)</TD>
    <TD>Per unit price or other
underlying value of transaction computed pursuant to Exchange Act Rule&nbsp;0-11 (set forth the amount on which the filing fee
is calculated and state how it was determined):</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>(4)</TD>
    <TD>Proposed maximum aggregate value of transaction:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>(5)</TD>
    <TD>Total fee paid:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD COLSPAN="2">Fee paid previously with preliminary materials.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD>
    <TD COLSPAN="2">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</TD></TR>

<TR STYLE="vertical-align: top; text-align: left"><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>                        <TR STYLE="vertical-align: top; text-align: left">
<TD>&nbsp;</TD>
    <TD>(1)</TD>
    <TD>Amount previously paid:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD>&nbsp;</TD>
    <TD>(2)</TD>
    <TD>Form, Schedule or Registration Statement No.:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD>&nbsp;</TD>
    <TD>(3)</TD>
    <TD>Filing Party:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD>&nbsp;</TD>
    <TD>(4)</TD>
    <TD>Date Filed:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">August 26, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Stockholder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You are cordially invited
to attend our Annual Meeting of Stockholders on Thursday, October 13, 2016, at 10:00 a.m. Pacific Daylight Time at the Avenue of
the Arts Hotel, 3350 Avenue of the Arts, Costa Mesa, California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This booklet includes
the Notice of Annual Meeting and the Proxy Statement. The Proxy Statement describes the business to be transacted at the Annual
Meeting and provides other information about Peregrine that you should know when you vote your shares. In addition to the formal
business to be transacted, management will make a presentation on developments during the past year and will respond to stockholder
questions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Your vote is very important
and we hope you will vote as soon as possible. There are three ways to vote by proxy&mdash;by Internet, by telephone, or by mailing
the proxy card. Voting instructions for each of these methods are on the proxy card.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Thank you for your
continued support and interest in Peregrine. We look forward to seeing you on Thursday, October 13, 2016 at our Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,</P>



</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><B><I><IMG SRC="image_003.jpg" ALT="" STYLE="width: 140px; height: 51px"></I></B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Steven W. King</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><I>&nbsp;</I></TD>
    <TD><I>President, Chief Executive Officer and Director</I></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I></I></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">14282 Franklin Avenue <FONT STYLE="font-size: 10pt">&#9679;</FONT>
Tustin, California 92780 <FONT STYLE="font-size: 10pt">&#9679; </FONT>(714) 508-6000<FONT STYLE="font-size: 10pt"> &#9679; </FONT>www.peregrineinc.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">14282 Franklin Avenue &#9679; Tustin,
California 92780</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; border-top: Black 0.5pt solid; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt; font-variant: small-caps"><B>Notice
of Annual Meeting of Stockholders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; border-bottom: Black 0.5pt solid; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>To Be Held on October 13, 2016</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid"><FONT STYLE="font-variant: small-caps"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TO THE STOCKHOLDERS OF PEREGRINE PHARMACEUTICALS,
INC.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notice is hereby given
that the Annual Meeting of the Stockholders of Peregrine Pharmaceuticals, Inc., a Delaware corporation, will be held on October
13, 2016 at 10:00 a.m. Pacific Daylight Time, at the Avenue of the Arts Hotel, 3350 Avenue of the Arts, Costa Mesa, California
92626, for the following purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 31.5pt">&nbsp;</TD>
    <TD STYLE="width: 18pt">1.</TD>
    <TD STYLE="text-align: justify">To elect four directors to our Board of Directors to serve until the next annual meeting and until their successors are
elected and qualified;</TD></TR>

<TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18pt">2.</TD><TD STYLE="text-align: justify">To ratify the Audit Committee&rsquo;s selection of Ernst&nbsp;&amp; Young LLP as our independent
registered public accounting firm for the fiscal year ending April 30, 2017;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18pt">3.</TD><TD STYLE="text-align: justify">To approve an amendment to our certificate of incorporation, as amended, to effect a reverse stock
split of the issued and outstanding shares of our common stock at a ratio to be established by our Board of Directors in its discretion,
of up to 1-for-7, subject to the Board of Directors&rsquo; discretion to abandon such amendment;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18pt">4.</TD><TD STYLE="text-align: justify">To approve an amendment to our 2010 Employee Stock Purchase Plan;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18pt">5.</TD><TD STYLE="text-align: justify">To approve, on an advisory basis, the compensation of our named executive officers, as disclosed
in our Proxy Statement for the 2016 Annual Meeting of Stockholders; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 31.5pt"></TD><TD STYLE="width: 18pt">6.</TD><TD STYLE="text-align: justify">To transact such other business as may properly come before the Annual Meeting or any adjournment
thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Only stockholders of
record at the close of business on August 19, 2016 are entitled to notice of, and to vote at, this Annual Meeting and any adjournment
or postponement thereof. <B>The Board of Directors recommends that you vote FOR each of the proposals identified above.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">By Order of the Board
of Directors,</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><B><I><IMG SRC="image_004.jpg" ALT="" STYLE="width: 158px; height: 51px"></I></B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Mark
R. Ziebell, <I>Vice President,</I> </TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><I>&nbsp;</I></TD>
    <TD><I>General Counsel and<B> </B>Corporate Secretary</I></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Tustin, California</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">August 26, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Important Notice Regarding the Availability
of Proxy Materials for</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>the Annual Meeting of Stockholders To
Be Held on October 13, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The Proxy Statement and the</B> <B>2016</B>
<B>Annual Report to Stockholders and the means to vote by Internet are available at www.proxyvote.com.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 25%; font-size: 10pt">&nbsp;</td>
    <td style="width: 24%; font-size: 10pt">&nbsp;</td>
    <td style="width: 24%; font-size: 10pt">&nbsp;</td>
    <td style="width: 24%; font-size: 10pt">&nbsp;</td>
    <td style="width: 3%; font-size: 10pt">&nbsp;</td></tr>
<tr>
    <td colspan="5" style="border: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.5pt 0pt 2.25pt; text-align: justify"><b>IMPORTANT: You are cordially
        invited to attend the meeting in person. Whether or not you expect to attend the meeting, please vote as soon as possible by using
        the Internet or telephone or for those receiving paper copies of these proxy materials by completing, signing, dating and mailing
        your proxy card in the accompanying postage-paid envelope. Even if you have voted by proxy, you may still vote in person if you
        attend the meeting. Please note, however, that if the record holder of your shares is a broker, bank or other nominee, and you
        wish to vote at the meeting, you must obtain a valid proxy issued in your name from that record holder.</b></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.5pt 0pt 2.25pt; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.5pt 0pt 2.25pt; text-align: justify"><b>Registration will begin
        at 9:30 a.m. Pacific Daylight Time. Each stockholder will need to bring the Admission Ticket included with your proxy card, voting
        instruction card or Notice Regarding the Availability of Proxy Materials for admission to the Annual Meeting.</b></P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B>This
Notice of Annual Meeting of Stockholders, Proxy Statement and accompanying proxy card are being distributed on or about
September 2, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&nbsp;<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: blue; border-top: Black 0.5pt solid; border-bottom: Black 0.5pt solid"><FONT STYLE="font-variant: small-caps; color: White"><B>Proxy
Statement</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">General Information</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Your vote is very
important.</U> For this reason, the Board of Directors of Peregrine Pharmaceuticals, Inc., a Delaware corporation (referred to
as &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; &ldquo;Company,&rdquo; or &ldquo;Peregrine<FONT STYLE="font-size: 10pt">&rdquo;</FONT>),
is soliciting your proxy to vote your shares of common stock at the 2016 Annual Meeting of Stockholders (the &ldquo;Annual Meeting&rdquo;),
or at any continuation, postponement or adjournment thereof, for the purposes discussed in this Proxy Statement and in the accompanying
Notice of Annual Meeting and any business properly brought before the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Web links and addresses
contained in this Proxy Statement are provided for convenience only, and the content on the referenced websites does not constitute
a part of this Proxy Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Why am I receiving these materials?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Proxies are
solicited to give all stockholders of record an opportunity to vote on matters properly presented at the Annual Meeting. This
Proxy Statement is being provided to all stockholders of record as of the close of business on August 19, 2016 in connection
with the solicitation of proxies on behalf of the Board of Directors for use at the Annual Meeting to be held on October 13,
2016. We intend to commence mailing this Proxy Statement and accompanying proxy card on or about September 2, 2016 to all
stockholders entitled to vote at the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">What are the Board of Directors&rsquo; voting recommendations?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the reasons set
forth in more detail later in the Proxy Statement, our Board of Directors recommends that you vote for the proposals as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the election of our four directors;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the ratification of the Audit Committee&rsquo;s selection of Ernst &amp; Young LLP as our independent
registered public accounting firm for the fiscal year ending April 30, 2017;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the approval of the amendment to our certificate of incorporation, as amended, to effect a reverse
stock split of the issued and outstanding shares of our common stock at a ratio to be established by our Board of Directors in
its discretion, of up to 1-for-7, subject to the Board of Directors&rsquo; discretion to abandon such amendment;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the approval of an amendment to our 2010 Employee Stock Purchase Plan; and</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the approval, on an advisory basis, of the compensation of our named executive officers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please note that if
you sign your proxy card and return it without indicating how you would like to vote your shares, your shares will be voted in
accordance with the Board of Directors&rsquo; recommendations stated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Why did I receive
a Notice Regarding the Availability of Proxy Materials instead of printed proxy materials?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As permitted by rules
adopted by the Securities and Exchange Commission (&ldquo;SEC&rdquo;), we are furnishing our Proxy Statement, 2016 Annual Report
to Stockholders and proxy card over the Internet to most of our stockholders. Accordingly, on or about September 2, 2016, we
will send a Notice Regarding the Availability of Proxy Materials (the &ldquo;Internet Notice&rdquo;) to most stockholders of record
and beneficial owners. These stockholders have the ability to access the proxy materials on a website referred to in the Internet
Notice or request to receive a printed set of the proxy materials by calling the toll-free number found in the Internet Notice.
We encourage you to take advantage of the availability of the proxy materials on the Internet in order to help reduce the cost
and environmental impact of the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>How can I get electronic
access to the proxy materials?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Internet Notice
provides you with instructions regarding how to: (1)&nbsp;view our proxy materials for the Annual Meeting on the Internet; (2)&nbsp;vote
your shares after you have viewed our proxy materials; (3)&nbsp;request a printed copy of the proxy materials; and (4)&nbsp;instruct
us to send our future proxy materials to you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Who is eligible to vote?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Common
stockholders of Peregrine, as recorded in our stock register at the close of business on August 19, 2016, can vote at the
Annual Meeting. Each share of Peregrine&rsquo;s common stock is entitled to one vote. As of August 19, 2016, there were
241,456,721 shares of our common stock outstanding and entitled to vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">How do I vote?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Voting by Internet.</I>
To vote by Internet, go to <FONT STYLE="color: #0563C1"><U>www.proxyvote.com</U></FONT>. Internet voting is available 24 hours
a day, 7 days a week, although your vote by Internet must be received by 11:59 p.m. Eastern Time on October 12, 2016. You will
need the control number found either on the Internet Notice or on the proxy card if you are receiving a printed copy of these materials.
If you vote by Internet, please do not return your proxy card or voting instruction card. If you hold your shares in &ldquo;street
name&rdquo;, as explained below, please refer to the Internet Notice or voting instruction card provided to you by your broker,
bank or other nominee for Internet voting instructions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Voting by Telephone.</I>
To vote by telephone, call 1-800-690-6903 and follow the instructions. Telephone voting is available 24 hours a day, 7 days a week,
although your vote by telephone must be received by 11:59 p.m. Eastern Time on October 12, 2016. You will need the control number
found either on the Internet Notice or on the proxy card if you are receiving a printed copy of these materials. If you vote by
telephone, please do not return your proxy card or voting instruction card. If you hold your shares in &ldquo;street name&rdquo;,
as explained below, please refer to the Internet Notice or voting instruction card provided to you by your broker, bank or other
nominee for telephone voting instructions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Voting by Mail.</I>
By completing, signing and returning the proxy card in the prepaid and addressed envelope enclosed with the proxy materials delivered
by mail, you are authorizing the individuals named on the proxy card to vote your shares at the Annual Meeting in the manner you
indicate. You are encouraged to sign and return the proxy card even if you plan to attend the Annual Meeting so that your shares
will be voted if you are unable to attend the Annual Meeting. If you receive more than one proxy card, it is an indication that
your shares are held in multiple accounts. Please complete, sign and return all proxy cards to ensure that all your shares are
voted. If you return your signed proxy card but do not indicate your voting preferences, the persons named on the proxy card will
vote the shares represented by that proxy as recommended by our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, you may
also vote in person at the Annual Meeting. We recommend you vote by proxy even if you plan to attend the Annual Meeting. You can
always change your vote at the Annual Meeting. Please note, however, that if your shares are held of record by a broker, bank,
dealer or other nominee, then you are the beneficial owner of shares held in &ldquo;street name&rdquo;. If your shares are held
in street name and you wish to vote in person at the Annual Meeting, you must obtain a valid proxy issued in your name from such
&ldquo;street name&rdquo; holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">How can I attend the Annual Meeting?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Registration will begin
at 9:30 a.m. Pacific Daylight Time on the date of the Annual Meeting. Each stockholder will need to bring the Admission Ticket
included with your proxy card, your voting instruction card or Internet Notice to attend the Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Who pays the cost of proxy solicitation?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors
is soliciting the enclosed proxy. We will make proxy solicitations by electronic or regular mail and we will bear the costs of
this solicitation. We will request that banks, brokerage houses, nominees and other fiduciaries nominally holding shares of our
common stock forward the proxy soliciting materials to the beneficial owners of such common stock and obtain authorization for
the execution of proxies. We will, upon request, reimburse such parties for their reasonable expenses in forwarding proxy materials
to the beneficial owners. In the event we decide to hire a service to solicit proxies, we would expect such service to cost less
than $10,000, plus reasonable and approved out-of-pocket expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">What is a proxy?</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Giving us your proxy
means you authorize us to vote your shares at the Annual Meeting in the manner you direct. You may vote for all, some or none of
our director candidates. You may also vote for or against the other proposals or abstain from voting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">How do I vote if I am a stockholder of record?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you are a stockholder
of record, you can specify how you want your shares voted on each proposal by marking the appropriate boxes on the proxy card.
Please review the voting instructions on the proxy card and read the entire text of the proposals and the positions of the Board
of Directors in the Proxy Statement prior to marking your vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If your proxy card
is signed and returned without specifying a vote or an abstention on a proposal, it will be voted according to the recommendation
of the Board of Directors on that proposal. The recommendation of the Board of Directors is shown for each proposal on the proxy
card.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">How do I vote if I am a beneficial owner?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you are the beneficial
owner of shares held of record by a broker, bank or other nominee, you have the right to direct your broker, bank or other nominee
on how to vote the shares. You should complete a Voting Instruction Card which your broker, bank or nominee is obligated to provide
you. If you wish to vote in person at the Annual Meeting, you must first obtain from the record holder a valid proxy issued in
your name.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Brokerage firms have
the authority to vote shares on routine matters for which their customers do not provide voting instructions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Can I revoke a proxy?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-weight: normal">To
revoke your proxy if you are a stockholder of record, you must (i) deliver written notice of revocation to our Corporate Secretary
at our principal executive offices, 14282 Franklin Avenue, Tustin, California 92780, before the Annual Meeting, (ii) deliver a
validly executed proxy with a later date that we receive prior to the Annual Meeting, or (iii)&nbsp;attend the Annual Meeting and
vote your shares in person. You may revoke your proxy at any time before your shares are voted. Attendance at the Annual Meeting
will not, by itself, revoke a valid proxy. If you hold shares through a &ldquo;street name&rdquo; holder, you must contact that
&ldquo;street name&rdquo; holder to revoke any prior voting instructions. You may also revoke any prior voting instructions by
voting in person at the Annual Meeting if you obtain a valid proxy as described in the paragraph under the heading &ldquo;How do
I vote if I am a beneficial owner?&rdquo; above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">What are &ldquo;broker non-votes&rdquo;?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Broker non-votes occur
when nominees, such as &ldquo;street name&rdquo; holders do not receive voting instructions from the beneficial owners at least
ten days before the Annual Meeting. If that happens, the street name holder may vote those shares only on &ldquo;routine&rdquo;
matters, such as the ratification of auditors. Street name holders cannot vote on non-routine matters unless they receive voting
instructions from beneficial owners, resulting in so-called &ldquo;broker non-votes.&rdquo; The effect of &ldquo;broker non-votes&rdquo;
on each of the proposals that will be considered at the Annual Meeting is described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that Proposal
No. 2 for the ratification of our independent registered public accounting firm and Proposal No. 3 to amend our certificate of
incorporation, as amended, are considered &ldquo;routine&rdquo; matters, and hence we do not expect that there will be a significant
number of &ldquo;broker non-votes&rdquo; on such proposals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Proposal No. 1 to elect
directors, Proposal No. 4 to amend our 2010 Employee Stock Purchase Plan, and Proposal No. 5 to approve, on an advisory basis,
the compensation of the named executive officers, are considered non-routine and the street name holder may not vote your shares
on these proposals if it does not receive instructions from you. If you do not provide voting instructions on these three
proposals, a broker non-vote will occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">What is a quorum?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to carry on
the business of the Annual Meeting, a quorum must be present. This means that at least a majority of the outstanding shares entitled
to vote on the record date must be present at the Annual Meeting, either by proxy or in person. Abstentions and broker non-votes
are counted as present at the Annual Meeting for purposes of determining whether we have a quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<B></B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What are
the voting requirements to elect the directors and to approve each of the proposals described in this Proxy Statement?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 47%; border-bottom: Black 2.5pt solid; vertical-align: bottom; text-align: left">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Proposal</b></P></td>
    <td style="width: 2%; text-align: justify">&nbsp;</td>
    <TD STYLE="width: 28%; border-bottom: Black 2.5pt solid; vertical-align: bottom; text-align: left">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Vote Required</b></P></td>
    <td style="width: 2%; text-align: center">&nbsp;</td>
    <TD STYLE="width: 21%; border-bottom: Black 2.5pt solid; text-align: center"><b>Broker Discretionary<BR>
 Voting Allowed</b></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">No. 1&mdash;Election of Directors</td>
    <td style="text-align: justify">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Plurality of votes cast</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(the four directors receiving the most &ldquo;For&rdquo; votes
        shall be elected)</P></td>
    <td style="text-align: justify">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">No</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">No. 2&mdash;Ratification of Ernst &amp; Young LLP</td>
    <td style="text-align: justify">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1pt solid">Majority of the shares present, in person or represented by proxy, and entitled to vote</td>
    <td style="text-align: justify">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">Yes</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">No. 3&mdash;Approval of an amendment to our certificate of incorporation, as
    amended,     to     effect a reverse stock split of the issued and outstanding shares of our common stock, at a ratio to be
    established by     our     Board of Directors in its discretion, of up to 1-for-7, subject to the Board of Directors&rsquo;
    discretion to     abandon such     amendment</td>
    <td style="text-align: justify">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1pt solid">Majority of the outstanding shares entitled to vote</td>
    <td style="text-align: justify">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">Yes</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">No. 4&mdash;Approval of an amendment to our 2010 Employee Stock Purchase Plan</td>
    <td style="text-align: justify">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1pt solid">Majority of the shares present, in person or represented by proxy, and entitled to vote</td>
    <td style="text-align: justify">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">No</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">No. 5&mdash;Advisory approval of executive compensation (non-binding)</td>
    <td style="text-align: justify">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1pt solid">Majority of the shares present, in person or represented by proxy, and entitled to vote</td>
    <td style="text-align: justify">&nbsp;</td>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">No</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Proposal No. 1&mdash;Election
of Directors. Directors are elected by a plurality of the votes of the shares of common stock present and entitled to vote, in
person or by proxy, at the Annual Meeting. Abstentions and &ldquo;broker non-votes&rdquo; will not be counted in determining which
nominees received the largest number of votes cast.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Proposal No. 2&mdash;Ratification
of Ernst &amp; Young LLP. A majority of the shares present, in person or represented by proxy, and entitled to vote must be voted
&ldquo;for&rdquo; the ratification of Ernst &amp; Young LLP as our independent registered public accounting firm to approve Proposal
No. 2. Abstention shares are considered votes present and entitled to vote and, as such, will have the same effect as a vote &ldquo;against&rdquo;
Proposal No. 2. Broker non-votes will have no effect on the vote to approve Proposal No. 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Proposal
No. 3&mdash;Approval of an amendment to our certificate of incorporation, as amended, to effect a reverse stock split of the
issued and outstanding shares of our common stock at a ratio to be established by our Board of Directors in its discretion,
of up to 1-for-7, subject to the Board of Directors&rsquo; discretion to abandon such amendment. A majority of the
outstanding shares of common stock entitled to vote must be voted &ldquo;for&rdquo; the amendment to our certificate of
incorporation, as amended, to approve Proposal No. 3. Abstentions and broker non-votes are both counted as votes
&ldquo;against&rdquo; Proposal No. 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Proposal No.
4&mdash;Approval of an amendment to our 2010 Employee Stock Purchase Plan. A majority of the shares present, in person or
represented by proxy, and entitled to vote must be voted &ldquo;for&rdquo; the approval of an amendment to our 2010 Employee
Stock Purchase Plan to approve Proposal No. 4. Abstention shares are considered votes present and entitled to vote and, as
such, will have the same effect as a vote &ldquo;against&rdquo; Proposal No. 4. Broker non-votes will have no effect on the
vote to approve Proposal No. 4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Proposal No. 5&mdash;Advisory
vote on fiscal year 2016 executive compensation. A majority of the shares present, in person or represented by proxy, and entitled
to vote must be voted &ldquo;for&rdquo; the approval, on an advisory basis, of the compensation of our Named Executive Officer
to approve Proposal No. 5. Abstention shares are considered votes present and entitled to vote and, as such, will have the same
effect as a vote &ldquo;against&rdquo; Proposal No. 5. Broker non-votes will have no effect on the vote to approve Proposal No.
5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">How are the votes counted?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All votes will be tabulated
by the inspector of election appointed for the Annual Meeting, who will separately tabulate affirmative and negative votes and
abstentions. Any information that identifies a stockholder or the particular vote of a stockholder is kept confidential.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">What is &ldquo;Householding&rdquo; of Annual Meeting materials?</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some &ldquo;street
name&rdquo; holders may be &ldquo;householding&rdquo; our proxy statements and annual reports. This means that only a single copy
of our Proxy Statement and Annual Report to stockholders may have been sent to two or more stockholders sharing the same address.
We will promptly deliver a separate copy of either document to you if you call or write us at our principal executive offices,
14282 Franklin Avenue, Tustin, California, 92780, Attn: Investor Relations, telephone: (800) 987-8256. If you would like to receive
separate copies of the Proxy Statement or Annual Report to stockholders in the future, or if you are receiving multiple copies
and would like to receive only one copy per household, please notify your bank, broker, or other nominee if your shares are held
in &ldquo;street name&rdquo;, or you may contact us at the above address and telephone number.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>How can I find out
the results of the voting at the Annual Meeting?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preliminary voting
results will be announced at the Annual Meeting. Final voting results will be published in a Current Report on Form 8-K to be filed
with the SEC within four business days after the Annual Meeting. If final voting results are not available to us in time to file
a Current Report on Form&nbsp;8-K within four business days after the Annual Meeting, we intend to file a Current Report on Form&nbsp;8-K
to publish preliminary results and, within four business days after the final results are known to us, file an additional Current
Report on Form&nbsp;8-K to publish the final results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: blue; border-top: Black 0.5pt solid"><FONT STYLE="font-variant: small-caps; color: White"><B>Proposal
No. 1:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: blue"><FONT STYLE="font-variant: small-caps; color: White"><B>Election
of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors
has nominated Mr. Carlton M. Johnson, Jr., Mr. Steven W. King, Mr. David H. Pohl, and Mr. Eric S. Swartz for election at the Annual
Meeting for a term of one (1) year to serve as a member of the Board of Directors until the 2017 Annual Meeting, and until their
respective successors are duly elected and qualified. There are four nominees for the four currently authorized seats on our Board
of Directors. Unless authority to vote for directors has been withheld in the proxy, the persons named in the enclosed proxy intend
to vote at the Annual Meeting <U>FOR</U> the election of the nominees presented below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Delaware law,
the four nominees receiving the highest number of votes will be elected as directors at the Annual Meeting. As a result, proxies
voted to &ldquo;Withhold Authority&rdquo; and broker non-votes will have no effect on the proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each person nominated
for election is currently serving as a director of Peregrine and each nominee has consented to serve as a director for the ensuing
year. If any nominee becomes unavailable to serve for any reason before the election, then the enclosed proxy will be voted for
the election of such substitute nominee, if any, as shall be designated by the Board of Directors. The Board of Directors has no
reason to believe that any of the nominees will become unavailable to serve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Information with respect
to the number of shares of common stock beneficially owned by each director as of August 12, 2016 appears under the heading &ldquo;Security
Ownership of Certain Beneficial Owners, Directors and Management.&rdquo; The name, age, year commenced service on our Board of
Directors, and principal occupation and business experience of each director nominee is set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DIRECTOR BIOGRAPHY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <TD STYLE="vertical-align: top; width: 16%; border-bottom: Black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Name and Age</b></P></td>
    <TD STYLE="vertical-align: bottom; width: 74%; border-bottom: Black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Principal Occupation and Business Experience</b></P></td>
    <TD STYLE="vertical-align: top; width: 10%; border-bottom: Black 1.5pt solid; text-align: center"><b>Director Since</b></td></tr>
<tr style="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carlton M. <BR>
Johnson, Jr.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(age 56)</P></td>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Mr. Johnson has served
        as a member of the Board of Directors since November 1999 and was appointed Chairman of the Board on October 22, 2010. Mr. Johnson
        has been self-employed since March 2013. Prior to that, he served as in-house legal counsel for Roswell Capital affiliated entities
        since June 1996. Mr. Johnson has been admitted to the practice of law in Alabama since 1986, Florida since 1988 and Georgia since
        1997. He has been a shareholder in the Pensacola, Florida AV- rated law firm of Smith, Sauer, DeMaria, Johnson and was President-Elect
        of the 500 member Escambia-Santa Rosa Bar Association. He also served on the Florida Bar Young Lawyers Division Board of Governors.
        Mr.&nbsp;Johnson earned a degree in History/Political Science at Auburn University and Juris Doctor at Samford University - Cumberland
        School of Law. Mr. Johnson also serves on the board of Patriot Scientific Corporation, and formerly served on the boards of CryoPort,
        Inc. (ceased in May 2012), and Ecotality, Inc. (ceased in March 2012). The Board of Directors concluded that Mr. Johnson should
        serve as a director in light of the extensive public company finance experience that he has obtained through serving on our board
        and audit committee and the boards and audit committees of Patriot Scientific Corporation, CryoPort, Inc. and Ecotality, Inc.,
        which represents over an aggregate of 36 years of combined public company board experience.</P></td>
    <TD STYLE="text-align: center; text-indent: 0in">1999</td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr><TD STYLE="vertical-align: top; width: 16%; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Name and Age</B></P></TD>
    <TD STYLE="vertical-align: bottom; width: 74%; border-bottom: Black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Principal Occupation and Business Experience</B></P></TD>
    <TD STYLE="vertical-align: top; width: 10%; border-bottom: Black 1.5pt solid; text-align: center"><B>Director Since</B></TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="width: 16%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven W. King</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(age 52)</P></td>
    <TD STYLE="width: 74%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. King has served as our President and
        Chief Executive Officer since March 2003 and as a member of the Board of Directors since October 2003. From August 2002 to March
        2003, Mr. King served as Chief Operating Officer and from February 2000 to August 2002 served as Vice President of Technology and
        Product Development. Mr. King joined Peregrine in 1997 as Director of Research and Development. Additionally, Mr. King was responsible
        for launching our wholly-owned biomanufacturing subsidiary, Avid Bioservices, Inc., in 2002, for which he serves as President.
        Mr. King was previously employed at Vascular Targeting Technologies, Inc., which was acquired by Peregrine in 1997. Mr. King previously
        worked at the University of Texas Southwestern Medical Center with Dr. Philip Thorpe, the inventor of our Phosphatidylserine (PS)-targeting
        antibody and VTA technology platforms and is co-inventor on over 40 U.S. and foreign patents and patent applications in the Vascular
        Targeting Agent field. Mr. King received his Bachelor&rsquo;s and Master&rsquo;s degrees from Texas Tech University in Cell and
        Molecular Biology. The Board of Directors concluded that Mr. King should serve as a director in light of his extensive scientific
        understanding of our technologies in development and expertise in developing and manufacturing biologics, combined with the perspective
        and experience he brings as our President and Chief Executive Officer from his extensive history with Peregrine.</P></td>
    <TD STYLE="text-align: center; text-indent: 0in; width: 10%">2003</td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David H. Pohl</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(age 79)</P></td>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Pohl has served as a member of the
        Board of Directors since October 2004. He is currently Chairman of the Board of Wellness.com, Inc., a privately held Internet-based
        health and wellness enterprise and serves on the Advisory Board of Max Sound Corporation, a public company and innovators of MAX-D
        HD Audio as well as licensor of other disruptive technologies. He was previously a member of the Board of Directors of Patriot
        Scientific Corporation from 2001 through 2008, and served as Chairman of the Board and CEO of that publicly traded company from
        2005 through 2007. Since 2009, Mr. Pohl has been Of Counsel with the law firm of Herold &amp; Sager in Encinitas, California. Mr.
        Pohl was in the private practice of law, counseling business clients from 1997 to 2005, and serving as Special Counsel to the Ohio
        Attorney General for entrepreneurial investments by state employee pension funds from 1995 to 1996. Previously, he was a Senior
        Attorney with Jones Day Reavis &amp; Pogue, a large U.S. law firm, and held positions as a Senior Officer and General Counsel in
        large financial services corporations with over $1 billion in assets under management. In addition, Mr. Pohl is a member of the
        Corporate Directors Forum of San Diego, the Intellectual Property Law and Business Law Sections of the State Bar of California,
        has served as a member of the Board of Governors of the Corporate Counsel Section of the Ohio State Bar Association, and is an
        Emeritus member of the Board of Directors of the American Financial Services Association, Washington, D.C. Mr. Pohl earned a Juris
        Doctor degree from The Ohio State University College of Law, and also holds a B.S. in Administrative Sciences from The Ohio State
        University. The Board of Directors concluded that Mr. Pohl should serve as a director in light of his extensive corporate governance
        experience.</P></td>
    <TD STYLE="text-align: center; text-indent: 0in">2004</td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Eric S. Swartz</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(age 60)</P></td>
    <TD STYLE="text-align: justify">Mr. Swartz has served as a member of the Board of Directors since 1999.&nbsp;&nbsp;With 33 years of experience in the securities business, Mr. Swartz is the co-founder and Manager of Roswell Capital Partners, LLC since 2004 and was the founder and former President of Equiplace Securities, LLC and Swartz Investments, LLC.&nbsp;&nbsp;From 1988 to 1993, Mr. Swartz was a Vice President at Bear Stearns &amp; Co. where he specialized in foreign institutional equity investments in U.S. securities.&nbsp;&nbsp;Previously, Mr. Swartz was a Vice President with Oppenheimer &amp; Co., where he was involved in overseas placements of equity and debt for institutions in Germany, Austria, Switzerland, France, Australia, and New Zealand.&nbsp;&nbsp;The Board of Directors concluded that Mr. Swartz should serve as a director in light of the extensive experience in corporate finance, including equity and debt placements, that he has obtained through his 33 years of experience in that industry.</td>
    <TD STYLE="text-align: center; text-indent: 0in">1999</td></tr>
</table>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Recommendation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>The
Board of Directors </B></FONT><B>UNANIMOUSLY <FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">RECOMMENDS
that stockholders VOTE <FONT STYLE="font-size: 10pt"><U>FOR</U></FONT> each DIRECTOR nominee named in proposal no.
1.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase; color: White"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: blue; border-top: Black 0.5pt solid; border-bottom: Black 0.5pt solid"><FONT STYLE="font-variant: small-caps; color: White"><B>Corporate
Governance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors
strongly believes in good corporate governance policies and practices. We expect to continue to seek and implement those corporate
governance practices that we believe will promote a high level of performance from our Board of Directors, officers and employees.
This section describes key corporate governance guidelines and practices that our Board of Directors has adopted. Copies of the
following corporate governance documents are posted on our website at www.peregrineinc.com: (1)&nbsp;Code of Business Conduct and
Ethics, (2)&nbsp; Amended and Restated Charter of the Compensation Committee of the Board of Directors, (3) Charter of the Audit
Committee of the Board of Directors, and (4)&nbsp; Charter of the Nominating Committee of the Board of Directors. If you would
like a printed copy of any of these corporate governance documents, please send your request to Peregrine Pharmaceuticals, Inc.,
Attention: Corporate Secretary, 14282 Franklin Avenue, Tustin, California 92780.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Board of Directors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business is managed
under the direction of our Board of Directors pursuant to the Delaware General Corporation Law and our Amended and Restated Bylaws
(&ldquo;Bylaws&rdquo;). Our Board of Directors has responsibility for establishing broad corporate policies and reviewing our overall
performance. Among the primary responsibilities of our Board of Directors is the oversight of the management of our Company. Our
directors remain informed of our business and management activities by reviewing documents provided to them before each meeting
of the Board of Directors and by attending presentations made by our chief executive officer and other members of management. The
Board of Directors held six (6) formal meetings during the fiscal year ended April 30, 2016. Each incumbent director attended at
least seventy-five percent (75%) of the meetings of the Board and of the committees on which he served during the fiscal year ended
April&nbsp;30, 2016. In addition, members of the Board of Directors have access to our books, records and reports and independent
auditors and advisors. Members of our management frequently interact with and are at all times available to our directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Director Independence</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under NASDAQ Listing
Rule 5605(a)(2), a director will not be considered an &ldquo;independent director&rdquo; if, such director at any time during the
past three years was an employee of the Company, or if a director (or a director&rsquo;s family member) accepted compensation from
the Company (other than compensation for board or committee service) in excess of $120,000 during any twelve consecutive month
period within the three years preceding the determination of independence. In addition, a director will not qualify as an &ldquo;independent
director&rdquo; if, in the opinion of our Board of Directors, that person has a relationship that would interfere with the exercise
of independent judgment in carrying out the responsibilities of a director. Our Board of Directors has determined that each of
the current directors, as well as those standing for re-election, are independent directors as defined by the NASDAQ Listing Rules
governing the independence of directors, except for Steven W. King, our President and Chief Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Audit, Compensation
and Nominating Committees are composed entirely of independent directors as required by applicable SEC and NASDAQ rules, including
Rule 10A-3 under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). In addition, there are
no family relationships among any of the directors or executive officers of the Company. Further, each member of our Compensation
Committee is a &ldquo;non-employee director&rdquo; under Section 16 of the Exchange Act and an &ldquo;outside director&rdquo; for
purposes of Section 162(m) of the Internal Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Meetings of Independent Directors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The independent members
of our Board of Directors have a practice of meeting in executive sessions without the presence of any members of Peregrine&rsquo;s
management. The independent members of the Board of Directors are scheduled to meet each time the Board of Directors holds its
regularly scheduled meetings and otherwise as needed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Committees of Our Board of Directors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors
has three standing committees: the Compensation Committee, the Audit Committee, and the Nominating Committee. Each of the three
committees maintains a written charter approved by the Board of Directors. Current copies of all of our committees&rsquo; charters
are available on our website at www.peregreineinc.com. The following is a summary of our three standing committees:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Compensation Committee</U><I>.</I>
The primary purpose of the Compensation Committee of the Board of Directors is to: (i) establish the compensation policy of the
Company; (ii) ensure that the compensation of the Board of Directors, Chief Executive Officer and other corporate officers of the
Company enables it to attract and retain high-quality leadership and is consistent with such policy; (iii) review the performance
and development of the Company&rsquo;s Chief Executive Officer and other corporate officers in achieving Company goals and objectives
and to ensure that senior executives of the Company are compensated effectively in a manner consistent with the strategy of the
Company; and (iv) produce an annual report on executive compensation for inclusion in the Company&rsquo;s proxy statements, in
accordance with applicable rules and regulations. The Compensation Committee met six (6) times during the fiscal year ended April
30, 2016, each coinciding with the formal meetings of the Board of Directors. The Compensation Committee has the authority to determine
director and executive compensation and may not delegate this authority. The Compensation Committee&rsquo;s members are currently
Messrs. Swartz (chairman of the committee), Johnson, and Pohl.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Audit Committee</U><I>.</I>
The Audit Committee of the Board of Directors has the sole authority for the appointment, compensation and oversight of the work
of the independent auditors, and responsibility for reviewing and discussing, prior to filing or issuance, with management and
the independent auditors (when appropriate) the Company&rsquo;s audited consolidated financial statements included in its Annual
Report on Form&nbsp;10-K. The Audit Committee carries out its responsibilities in accordance with the terms of its charter. The
Audit Committee met six (6) times during the fiscal year ended April 30, 2016, each coinciding with the formal meetings of the
Board of Directors. The Audit Committee of our Board of Directors has determined that Mr. Johnson is an &ldquo;audit committee
financial expert&rdquo; as defined by the SEC. The Audit Committee meets the NASDAQ composition requirements, including the requirement
that all Audit Committee members have the ability to read and understand financial statements. The current Audit Committee members
are Messrs. Johnson (chairman of the committee), Pohl and Swartz.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Nominating Committee</U>.
The primary purposes of the Nominating Committee of the Board of Directors are to: (i) make recommendations to the Board of Directors
regarding the size of the Board of Directors, (ii) make recommendations to the Board of Directors regarding criteria for the selection
of director nominees, (iii) identify and recommend to the Board of Directors for selection as director nominees individuals qualified
to become members of the Board of Directors, including stockholder recommendations, and (iv) recommend committee assignments to
the Board of Directors. The qualities and skills sought in prospective members of the Board of Directors will be determined by
the independent directors. Generally, director candidates must be qualified individuals who, if added to the Board of Directors,
would provide the mix of director characteristics, experience, perspective and skills appropriate for the Company. Criteria for
selection of candidates will include, but not be limited to: (i) business and financial acumen, as determined by the committee
in its discretion, (ii) qualities reflecting a proven record of accomplishment and ability to work with others, (iii) knowledge
of the Company&rsquo;s industry, (iv) relevant experience and knowledge of corporate governance practices, and (v) expertise in
an area relevant to the Company. The Nominating Committee does not have a written policy with respect to Board of Directors diversity;
however, the committee&rsquo;s goal is to assemble a Board of Directors that brings to the Company a diversity of knowledge, skills
and expertise derived from high quality business and professional experience. We believe a Board of Directors with these attributes
leads to improved Company performance by encouraging new ideas and perspectives and expanding the knowledge base available to management.
The Nominating Committee met two (2) times during the fiscal year ended April 30, 2016, each coinciding with formal meetings of
the Board of Directors. The Nominating Committee&rsquo;s members are Messrs. Pohl (chairman of the committee), Johnson, and Swartz.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-weight: normal">In
accordance with our Bylaws, stockholders may nominate a candidate for election as director by complying with certain notice and
other requirements set forth therein. For a stockholder to make any nomination for election to the Board of Directors at the 2017
Annual Meeting of Stockholders, the stockholder must provide notice to the Company, which notice must be delivered to, or mailed
and received at, the Company&rsquo;s principal executive offices not earlier than the close of business on June 15, 2017 and not
later than the close of business on August 15, 2017. However, if the 2017 Annual Meeting of Stockholders is not held between September
13, 2017 and November 12, 2017, the notice must be delivered no earlier than the close of business on the 120th day nor later than
the close of business on the 90th day prior to the 2017 Annual Meeting of Stockholders or, if later, the 10th day following the
day on which public disclosure of the date of the 2017 Annual Meeting of Stockholders is made. All such notices must be submitted
in accordance with the specific procedural requirements in our Bylaws and must include certain information with regard to the person
submitting the proposal. Further updates and supplements to such notice may be required at the times, and in the forms, required
under our Bylaws. As set forth in our Bylaws, submissions must include (i) the name, age, business address and residence address
of such nominee, (ii) the principal occupation or employment of such nominee, (iii) the class and number of shares of each class
of capital stock of the Company which are owned of record and beneficially by such nominee, (iv) the date or dates on which such
shares were acquired and the investment intent of such acquisition, (v) with respect to each nominee for election or re-election
to the Board of Directors, include a completed and signed questionnaire, representation and agreement required by our Bylaws, and
(vi) such other information concerning such nominee as would be required to be disclosed in a proxy statement soliciting proxies
for the election of such nominee as a director in an election contest (even if an election contest is not involved), or that is
otherwise required to be disclosed pursuant to Section 14 of the Exchange Act and the rules and regulations promulgated thereunder
(including such person&rsquo;s written consent to being named as a nominee and to serving as a director if elected). Our Bylaws
also specify further requirements as to the form and content of a stockholder&rsquo;s notice. We recommend that any stockholder
wishing to make a nomination for director review a copy of our Bylaws, which is available, without charge, from our Corporate Secretary,
at Peregrine Pharmaceuticals, Inc., 14282 Franklin Avenue, Tustin, California 92780.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-weight: normal">If
the Nominating Committee or the Board of Directors determines that any nomination made by a stockholder was not made in accordance
with the proper procedures under our Bylaws, the rules and regulations promulgated under the SEC or other applicable laws or regulations,
such nomination will be void. The Nominating Committee will evaluate candidates recommended by stockholders in the same manner
as those recommended by others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Board of Directors Leadership Structure</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors
does not have a policy on whether the same person should serve as both the Chief Executive Officer and Chairman of the Board of
Directors or, if the roles are separate, whether the Chairman should be selected from the non-employee directors or should be an
employee. The Board of Directors believes that it should have the flexibility to make these determinations in the way that it believes
best provides appropriate leadership for the Company at a given time.&nbsp; The Board of Directors believes that its current leadership
structure, with Mr.&nbsp;King serving as President and Chief Executive Officer and Mr.&nbsp;Johnson, an independent director, serving
as Chairman, is appropriate for the Company at this time because (i) both leaders are actively engaged on significant matters affecting
the Company and (ii) the Chief Executive Officer has overall responsibility for all aspects of the Company&rsquo;s operations,
while the Chairman has a greater focus on governance of the Company, including oversight of the Board of Directors, and we believe
this balance of shared leadership between the two positions is a strength for the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Risk Oversight</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors
oversees an enterprise-wide approach to risk management that is designed to support the achievement of organizational objectives
to improve long-term performance and enhance stockholder value. A fundamental part of risk management is not only understanding
the risks a company faces and what steps management is taking to manage those risks, but also understanding what level of risk
is appropriate for the Company. In setting the Company&rsquo;s business strategy, the Board of Directors assesses the various risks
being mitigated by management and determines what constitutes an appropriate level of risk for the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While the Board of
Directors has the ultimate oversight responsibility for the risk management process, various committees of the Board of Directors
also have responsibility for risk management. In particular, the Audit Committee focuses on financial risk, including internal
controls, and receives financial risk assessment reports from management. Risks related to the compensation programs are reviewed
by the Compensation Committee. The Board of Directors is advised by these committees of significant risks and management&rsquo;s
response via periodic updates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Communicating with the Board of Directors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under our Code of Business
Conduct and Ethics, we have established an Open Door Policy and Hotline For Reporting Employee Complaints or Accounting or Auditing
Matters for the confidential, anonymous submission by our directors, officers and employees of concerns regarding violations or
suspected violations of our Code of Business Conduct and Ethics, including matters relating to accounting and auditing matters.
In addition, the Audit Committee has established procedures for the receipt, retention and treatment of communications received
by us, our Board of Directors and the Audit Committee regarding accounting, internal controls or auditing matters. Written communications
from our stockholders and employees may be sent to: Peregrine Pharmaceuticals, Inc., Attention: Audit Committee Chair, 14282 Franklin
Avenue, Tustin, California 92780.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the Company&rsquo;s
annual meeting of stockholders provides an opportunity each year for stockholders to ask questions of or otherwise communicate
directly with members of the Board of Directors on appropriate matters. In addition, stockholders may communicate in writing with
any particular director, or the directors as a group, by sending such written communication to: Board of Directors, Attention:
Corporate&nbsp;Secretary, Peregrine Pharmaceuticals, Inc., 14282 Franklin Avenue, Tustin, California 92780. Copies of written communications
received at such address will be provided to the Board of Directors or the relevant director unless such communications are considered,
in the reasonable judgment of the Secretary, to be inappropriate for submission to the intended recipient(s). Examples of stockholder
communications that would be considered inappropriate for submission to the Board of Directors include, without limitation, customer
complaints, solicitations, communications that do not relate directly or indirectly to the Company&rsquo;s business or communications
that relate to improper or irrelevant topics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Director Attendance at Annual Meetings of Stockholders</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have no policy requiring
directors to attend annual meetings of stockholders, but directors are encouraged to attend our annual meetings at which they stand
for re-election. Each of our four directors attended the 2015 Annual Meeting of Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: blue; border-top: Black 0.5pt solid; border-bottom: Black 0.5pt solid"><FONT STYLE="font-variant: small-caps; color: White"><B>Director
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 4.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 4.5pt"><B>Director Compensation
Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 4.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to our compensation
program for non-employee directors, during the fiscal year ended April 30, 2016, each member of our Board of Directors who was
not an employee or officer of the Company received an annual cash retainer, paid in monthly installments, of $180,000 per year.
In addition, each non-employee director received a separate annual cash retainer related to their board membership and oversight
of our wholly-owned subsidiary, Avid Bioservices, Inc. (&ldquo;Avid&rdquo;), paid in monthly installments, of $60,000 per year.
Moreover, for their services as chairperson of their respective committees, the chairman of the Audit Committee, the chairman of
the Compensation Committee, and the chairman of the Nominating Committee received an additional annual cash retainer, paid in monthly
installments, of $90,000, $60,000, and $30,000 per year, respectively. Furthermore, each non-employee director received a cash
fee of $2,000 per day for each Board of Directors meeting attended, whether in-person or telephonically, and is entitled to receive
a cash fee of $2,000 for each additional Company meeting attended in excess of four hours in length. A member of the Board of Directors
who is also our employee receives no additional compensation for serving as a director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to our compensation
program for non-employee directors, each non-employee director participates in our routine annual broad-based stock option grant
program. The grant to each non-employee director: (i) consists of a non-qualified stock option to purchase a number of shares of
common stock as determined by the Compensation Committee; (ii) has an exercise price equal to the fair market value of our common
stock on the date of grant; and (iii) typically vests in quarterly increments over a two-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the
Company reimburses its non-employee directors for their out-of-pocket expenses incurred in connection with attending Board of Directors
and committee meetings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 4.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Director Compensation
Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
outlines the compensation paid to our non-employee directors, including annual base retainer fees, meeting attendance fees, and
option awards for the fiscal year ended April 30, 2016:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; background-color: White">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid">Name</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Fees Earned or</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Paid in Cash ($)</P></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Option</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Awards ($) <sup>(1)</sup></P></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Total ($)</P></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 28%; text-align: left">Carlton M. Johnson, Jr.</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: center">350,000 <sup>(2)</sup></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: center">198,038</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: center">548,038</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">David H. Pohl</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">290,000 <sup>(3)</sup></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">198,038</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">488,038</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Eric S. Swartz</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">320,000 <sup>(4)</sup></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">198,038</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">518,038</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">__________________________________</P>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; background-color: White">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top; width: 0.5in">(1)</TD>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">As to each individual, represents the grant date fair value of
    the option award granted in the fiscal year ended April 30, 2016 as computed in accordance with FASB ASC Topic 718. The
    assumptions used in determining the grant date fair values of the option awards are set forth in Note 6 &ldquo;Equity
    Compensation Plans&rdquo; in our Annual Report on Form 10-K for the fiscal year ended April 30, 2016, as filed with the SEC
    on July 14, 2016. In addition, these amounts do not correspond to the actual value that may be recognized by the
    non-employee director. As of April 30, 2016, each non-employee director held unexercised option awards covering
    1,719,500 shares of common stock.</font></TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">(2)</TD>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Includes annual base retainers of $240,000 (including Avid annual base retainer), the annual Audit Committee chair fee of $90,000 and meeting fees of $20,000.</font></TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">(3)</TD>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Includes annual base retainers of $240,000 (including Avid annual base retainer), the annual Nominating Committee chair fee of $30,000 and meeting fees of $20,000.</font></TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top">(4)</TD>
    <TD STYLE="text-align: justify"><font style="font-size: 10pt">Includes annual base retainers of $240,000 (including Avid annual base retainer), the annual Compensation Committee chair fee of $60,000 and meeting fees of $20,000.</font></TD>
    </TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: blue; border-top: Black 0.5pt solid; border-bottom: Black 0.5pt solid"><FONT STYLE="font-variant: small-caps; color: White"><B>Proposal
No. 2:<BR>
Ratification of Selection of Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Audit Committee,
in consultation with management, has approved the selection of Ernst &amp; Young LLP as our independent registered public accounting
firm for the fiscal year ending April 30, 2017, subject to ratification by our stockholders. Ernst &amp; Young LLP has served in
this capacity for each of the sixteen years ended April 30, 2016. During the sixteen fiscal years ended April 30, 2016, there were
no disagreements between the Company and Ernst &amp; Young LLP on any matter of accounting principles or practices, financial statement
disclosure or auditing scope or procedure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Representatives of
Ernst &amp; Young LLP are expected to be present at the Annual Meeting with the opportunity to make a statement if they desire
to do so and are expected to be available to respond to appropriate questions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stockholder ratification
of the selection of Ernst&nbsp;&amp; Young LLP as the Company&rsquo;s independent auditors is not required by the Bylaws or otherwise.
However, the Board of Directors is submitting the selection of Ernst &amp; Young LLP to the stockholders for ratification
as a matter of corporate practice. If the stockholders fail to ratify the selection, the Audit Committee will reconsider whether
or not to retain that firm. Even if the selection is ratified, the Audit Committee in its discretion may direct the selection of
a different independent accounting firm at any time during the year if the Audit Committee determines that such a change would
be in the best interests of the Company and its stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Recommendation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THE BOARD OF DIRECTORS
UNANIMOUSLY RECOMMENDS <FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">THAT Stockholders </FONT>VOTE
<FONT STYLE="font-size: 10pt"><U>FOR</U></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">
PROPOSAL No. 2 TO RATIFY THE selection OF Ernst &amp; Young LLP AS THE COMPANY&rsquo;S INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM FOR the FISCAL YEAR ENDING APRIL 30, 2017.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">&nbsp;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">&nbsp;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">&nbsp;</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"></FONT></B></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">&nbsp;</FONT></B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Independent Registered Public Accounting Firm Fees</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summarizes
aggregate fees billed to the Company for the fiscal years ended April 30, 2016 and 2015 by Ernst &amp; Young LLP, our independent
registered public accounting firm:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 16%; text-align: justify">Audit fees (1)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">496,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">535,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Audit-related fees (2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: justify">Tax fees (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">All other fees (4)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Total fees</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">498,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">537,000</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">______________</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Audit fees pertain to the audit of our annual consolidated financial statements for the fiscal
years ended April 30, 2016 and 2015, including attestation services relating to the report on our internal controls in accordance
with Section 404 of the Sarbanes-Oxley Act of 2002, and timely reviews of our quarterly consolidated financial statements, consents,
comfort letters, and review of documents filed with the SEC, including registration statements on Form S-3 and Form S-8.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">This category consists of fees for assurance and related services reasonably related to the performance
of the audit or review of financial statements and that are not reported under the Audit Fees category. We did not incur any fees
in this category for the fiscal years ended April 30, 2016 and 2015.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">This category consists of fees for professional services rendered for tax compliance and tax advice.
We did not incur any fees in this category for the fiscal years ended April 30, 2016 and 2015.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(4)</TD><TD STYLE="text-align: justify">All other fees are attributable to the Company&rsquo;s subscription to an Ernst &amp; Young LLP
online service used for accounting research purposes for the fiscal years ended April 30, 2016 and 2015.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pre-Approval Policy for Services Provided by our Independent
Registered Public Accounting Firm</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Audit Committee
has established a policy to pre-approve all audit and permissible non-audit services provided by our independent registered public
accounting firm consistent with applicable SEC rules. From and after the effective date of the SEC rule requiring Audit Committee
pre-approval of all audit and permissible non-audit services provided by an independent registered public accounting firm, the
Audit Committee has pre-approved all audit and permissible non-audit services provided by Ernst &amp; Young LLP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ernst &amp; Young LLP
did not perform any professional services with respect to information systems design and implementation for the years ended April
30, 2016 and 2015. The Audit Committee has considered whether the services provided by Ernst &amp; Young LLP are compatible with
maintaining that firm&rsquo;s independence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Report of the Audit Committee of the Board of Directors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Audit Committee
reviews the Company&rsquo;s financial matters and oversees the financial reporting process on behalf of our Board of Directors.
The Audit Committee operates pursuant to a written Audit Committee Charter. In accordance with the Audit Committee Charter, we
must meet the independence requirements and other criteria set by the NASDAQ Listing Rules and SEC rules as currently in effect.
As part of our oversight of our Company&rsquo;s financial statements, our Chairman of the Audit Committee reviews and discusses
with both management and Ernst &amp; Young LLP all annual and quarterly financial statements prior to their issuance. Our responsibilities
include selecting, in consultation with management, an accounting firm to be hired as the Company&rsquo;s independent registered
public accounting firm. We are also responsible for recommending to the Board of Directors that the Company&rsquo;s financial statements
be included in its Annual Report. We have taken the following steps in making our recommendation that the Company&rsquo;s financial
statements be included in its Annual Report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">Reviewed and discussed with both management and Ernst &amp; Young LLP, the Company&rsquo;s independent
registered public accounting firm, for the fiscal year ended April 30, 2016, all annual and quarterly financial statements prior
to their issuance.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Discussed with Ernst &amp; Young LLP those matters required to be discussed by Statement on Auditing
Standards No. 16, <I>Communications with Audit Committees</I>, as amended, and as adopted by the Public Company Accounting Oversight
Board (&ldquo;PCAOB&rdquo;) in Rule 3200T, including information regarding the scope and results of the audit. These communications
and discussions are intended to assist the Audit Committee in overseeing the financial reporting and disclosure process.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Discussed with Ernst &amp; Young LLP its independence and received from Ernst &amp; Young LLP the
written disclosures required by the PCAOB Ethics and Independence Rule 3526, <I>Communications with Audit Committees Concerning
Independence</I>. This discussion and disclosure helped the Audit Committee in evaluating such independence.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">Reviewed and discussed with the Company&rsquo;s management and Ernst &amp; Young LLP, the Company&rsquo;s
audited consolidated balance sheet at April 30, 2016, and consolidated statements of operations and comprehensive loss, cash flows
and stockholders&rsquo; equity for the fiscal year ended April 30, 2016.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the reviews
and discussions explained above, the Audit Committee recommended to the Board of Directors that the Company&rsquo;s financial statements
be included in its Annual Report on Form 10-K for the fiscal year ended April 30, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This report of the
Audit Committee shall not be deemed incorporated by reference by any general statement incorporating by reference this Proxy Statement
into any filing under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), or the Exchange Act, except to
the extent we specifically incorporate this information by reference, and shall not otherwise be deemed filed under either the
Securities Act or the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Audit Committee of the Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Carlton M. Johnson Jr. (Chairman)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David H. Pohl</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Eric S. Swartz</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: blue; border-bottom: Black 0.5pt solid"><FONT STYLE="font-variant: small-caps; color: White"><B>Proposal
No. 3: </B></FONT><BR>
<FONT STYLE="font-variant: small-caps; color: White"><B> Approval Of Amendment To Our Certificate Of Incorporation, as Amended,
To Effect A Reverse Stock Split at a Ratio to be Established by Our Board of Directors in its Discretion, of Up to 1-for-7,
Subject to the Board of directors&rsquo; discretion to abandon such amendment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Introduction</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors
has unanimously authorized and approved, and is submitting for stockholder approval, a proposal to amend our certificate of incorporation,
as amended, to effect a reverse stock split of our issued and outstanding common stock at a ratio to be established by our Board
of Directors in its discretion, of up to 1-for-7 (the &ldquo;Reverse Split&rdquo;), and to grant the Board of Directors discretionary
authority, until our 2017 annual meeting of stockholders, to determine whether or not to effect the Reverse Split and the exact
whole number ratio within the range at which to effect the Reverse Split. In setting the ratio for the Reverse Split, the intention
of our Board of Directors would be to increase the trading price of our common stock sufficiently above the $1.00 minimum bid price
that is required for continued listing on The NASDAQ Capital Market in order to reduce the risk that our common stock is delisted
from The NASDAQ Capital Market and to sustain long term compliance with the listing rules of The NASDAQ Stock Market LLC (&ldquo;NASDAQ&rdquo;)
The full text of the proposed amendment is attached hereto as <U>Exhibit A</U> (the &ldquo;Amendment&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Board of
Directors implements the Reverse Split, the exact ratio for the Reverse Split will be fixed by the Board of Directors. We
believe that this discretion is essential because it provides the Board of Directors with the maximum flexibility to react to
changing market conditions and to therefore act in the best interests of our Company and our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One principal effect
of the Reverse Split would be to decrease the number of outstanding shares of our common stock. Except for minimal adjustments
that may result from the treatment of fractional shares as described below, the Reverse Split will not have any dilutive effect
on our stockholders since each stockholder would hold the same percentage of common stock outstanding immediately following the
Reverse Split as such stockholder held immediately prior to the Reverse Split. The relative voting and other rights that
accompany the shares of common stock would not be affected by the Reverse Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although the Reverse
Split will not have any dilutive effect on our stockholders, the proportion of shares owned by our stockholders relative to the
number of shares authorized for issuance will decrease. As a result, the additional authorized shares of common stock will
be available for issuance at such times and for such purposes as the Board of Directors may deem advisable without further action
by our stockholders, except as required by applicable laws and regulations. We do not have any present plan or intention
to issue the additional shares of authorized but unissued common stock that would become available as a result of the proposed
Reverse Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Reverse Split is
not intended as, and will not have the effect of, a &ldquo;going private transaction&rdquo; subject to Rule 13e-3 under the Exchange
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Reasons for the Reverse Split</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Director&rsquo;s
primary objective in proposing the Reverse Split is to increase the per share trading price of our common stock on The NASDAQ Capital
Market. The Board of Directors believes that by increasing the price per share of our common stock, the Company may
meet and maintain compliance with the listing requirements of The NASDAQ Capital Market. The Board of Directors
believes that the liquidity and marketability of our common stock will be adversely affected if it is not quoted on a national
securities exchange, as investors can find it more difficult to dispose of, or to obtain accurate quotations as to the market value
of, our common stock. The Board of Directors believes that current and prospective investors will view an investment
in our common stock more favorably if our common stock remains quoted on The NASDAQ Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of
Directors also believes that the Reverse Split and any resulting increase in the per share price of our common stock should
also enhance the acceptability and marketability of our common stock to the financial community and investing public. Many
institutional investors have policies prohibiting them from holding lower-priced stocks in their portfolios, which reduces
the number of potential buyers of our common stock. Additionally, analysts at many brokerage firms are reluctant to recommend
lower-priced stocks to their clients or monitor the activity of lower-priced stocks. Brokerage houses also frequently have
internal practices and policies that discourage individual brokers from dealing in lower-priced stocks. Further, because
brokers&rsquo; commissions on lower-priced stock generally represent a higher percentage of the stock price than commissions
on higher priced stock, investors in lower-priced stocks pay transaction costs which are a higher percentage of their total
share value, which may limit the willingness of individual investors and institutions to purchase our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If effected, we cannot
assure you that the Reverse Split will have any of the desired effects described above. More specifically, we cannot
assure you that after the Reverse Split the trading price of our common stock will increase proportionately to reflect the ratio
for the Reverse Split, that the trading price of our common stock will not decrease to its pre-Reverse Split level, that our market
capitalization will be equal to the market capitalization before the Reverse Split, or that we will be able to maintain our listing
on The NASDAQ Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NASDAQ Requirements for Continued Listing on The NASDAQ Capital
Market</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is
currently traded on The NASDAQ Capital Market. On April 12, 2016 we received a letter from the staff of the Listing Qualifications
Department (the &ldquo;Staff&rdquo;) of NASDAQ notifying us that, for the previous 30 consecutive business days, the bid price
for our common stock had closed below the minimum $1.00 per share requirement for continued listing on The NASDAQ Capital Market
under NASDAQ&rsquo;s Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share (the &ldquo;Minimum Bid Price
Requirement&rdquo;). In accordance with NASDAQ Listing Rule 5810(c)(3)(A), if during the 180 calendar days following the date of
the notification, or prior to October 10, 2016, the closing bid price of our common stock is at or above $1.00 for a minimum of
10 consecutive business days, but generally no more than 20 consecutive business days, the Staff will provide us with written confirmation
of compliance. If we do not achieve compliance with the Minimum Bid Price Requirement by October 10, 2016, we may be eligible for
an additional 180 calendar days compliance period if we meet the continued listing requirement for market value of publicly held
shares and all other initial listing standards for The NASDAQ Capital Market, with the exception of the Minimum Bid Price Requirement,
and provide written notice of our intention to cure the minimum bid price deficiency during the second compliance period, by effecting
a reverse stock split, if necessary. However, if it appears to the Staff that we will not be able to cure the deficiency, or if
we are otherwise not eligible, the Staff would notify us that our common stock would be subject to delisting. In the event of such
notification, we may appeal the Staff&rsquo;s determination to delist our common stock, but there can be no assurance the Staff
would grant our request for continued listing. If our common stock were to be delisted, the liquidity of our common stock would
be adversely affected and the trading price of our common stock could decrease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors
has considered the potential harm to the Company of a delisting from The NASDAQ Capital Market and believes it is in the best interests
of the Company and our stockholders for the Company to regain compliance with the minimum bid price listing standard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Potential Disadvantages of a Reverse Stock Split</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As noted above, the
principal purpose of the Reverse Split would be to help increase the trading price per share of our common stock by a factor of
up to seven. We cannot assure you, however, that the Reverse Split will accomplish this objective for any meaningful
period of time.&nbsp;&nbsp;While we expect that the reduction in the number of outstanding shares of common stock will increase
the trading price of our common stock, we cannot assure you that the Reverse Split will increase the trading price of our common
stock by a multiple equal to the Reverse Split ratio to be determined by the Board of Directors, or result in any permanent increase
in the trading price of our common stock, which is dependent upon many factors, including our business and financial performance,
general market conditions, and prospects for future success. Should the trading price decline after the Reverse Split,
the percentage decline may be greater, due to the smaller number of shares outstanding, than it would have been prior to the Reverse
Split. In some cases, the per share stock price of companies that have effected reverse stock splits has subsequently
declined back to pre-reverse split levels. In addition, a reverse stock split is often viewed negatively by the market
and, consequently, can lead to a decrease in our overall market capitalization. If the per share trading price does
not increase proportionately as a result of the Reverse Split, then the value of the Company as measured by our stock capitalization
will be reduced, perhaps significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of
shares held by each individual stockholder would be reduced if the Reverse Split is implemented. This will
increase the number of stockholders who hold less than a &ldquo;round lot,&rdquo; or 100 shares. Typically, the transaction
costs to stockholders selling &ldquo;odd lots&rdquo; are higher on a per share basis. Consequently, the Reverse
Split could increase the transaction costs to existing stockholders in the event they wish to sell all or a portion of their
position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although the Board
of Directors believes that the decrease in the number of shares of our common stock outstanding as a consequence of the Reverse
Split and the anticipated increase in the trading price of our common stock could encourage interest in our common stock and possibly
promote greater liquidity for our stockholders, such liquidity could also be adversely affected by the reduced number of shares
outstanding after the Reverse Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Effecting the Reverse Split; Board Discretion to Implement
Reverse Split</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If approved by stockholders
at the Annual Meeting and our Board of Directors decide that it is in the best interests of the Company and our stockholders to
effect the Reverse Split, the Board of Directors will establish an appropriate ratio for the Reverse Split based on several factors
existing at such time and the Company will subsequently file the Amendment. Our Board of Directors will consider, among other factors,
prevailing market conditions, the likely effect of the Reverse Split on the trading price of our common stock, and on our compliance
with applicable NASDAQ listing requirements, and the marketability and liquidity of our common stock. The Board of Directors
will determine the timing of the filing of the Amendment with the Secretary of State of the State of Delaware to effect the Reverse
Split.&nbsp;If, for any reason, the Board of Directors deems it advisable, the Board of Directors, in its sole discretion, may
abandon the Reverse at any time prior to the effectiveness of any filing of the Amendment, without further action by our stockholders.&nbsp;&nbsp;The
Reverse Split will be effective as of the date and time set forth in the Amendment (the &ldquo;Effective Time&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the filing of
the Amendment, without further action on the part of the Company or the stockholders, the outstanding shares of common stock held
by stockholders of record as of the Effective Time would be converted into a lesser number of shares of common stock calculated
in accordance with the terms of the Amendment, based on a reverse split ratio not to exceed 1-for-7. In the event of
a Reverse Split at a ratio of 1-for-7, for example, if a stockholder holds 7,000 shares of common stock as of the Effective Time,
such stockholder would hold 1,000 shares of common stock following such Reverse Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Effect on Outstanding Shares, Options, and Certain Other
Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Reverse Split
is implemented, the number of shares of our common stock owned by each stockholder will be reduced in the same proportion as the
reduction in the total number of shares outstanding, such that the percentage of our common stock owned by each stockholder will
remain unchanged except for any de minimis change resulting from the issuance of one whole share in exchange for any fractional
shares that such stockholder would have received as a result of the Reverse Split.&nbsp;&nbsp;The number of shares of common stock
that may be purchased upon exercise of outstanding options or other securities convertible into, or exercisable or exchangeable
for, shares of our common stock, and the exercise or conversion prices for these securities, will also be adjusted in accordance
with their terms, as of the Effective Time. Additionally, the aggregate number of equity-based awards that remain available to
be granted under our equity incentive plans and other benefit plans will be reduced proportionately to reflect the Reverse Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the
Amended and Restated Rights Agreement (the &ldquo;Rights Agreement&rdquo;), dated as of March 16, 2016 between the
Company and Broadridge Corporate Issuer Solutions, Inc. (the &ldquo;Rights Agent&rdquo;), following the
Reverse Split, the number of rights (&ldquo;Rights&rdquo;) associated with each share of our common stock issued and
outstanding will be proportionately increased by the factor of the Reverse Split. For example, if the Reverse
Split is effected at a ratio of 1-for-7, then each share of common stock, which currently has five (5) Rights due to our
1-for-5 reverse stock split on October 16, 2009, following the Reverse Split will have seven 35 Rights. In
accordance with Section 12 of the Rights Agreement, this Proxy Statement will also serve as the certificate relating to
an adjustment of Rights that is required to be filed&nbsp;with the Rights Agent and mailed to each stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Reverse
Split will not change the number of shares of our 10.5% Series E Convertible Preferred Stock (the &ldquo;Series E Preferred
Stock&rdquo;) issued and outstanding; however, pursuant to the Certificate of Designations and Rights and Preferences of our
Series E Preferred Stock, the general conversion right with respect to the Series E Preferred Stock of $3.00 per share,
following the Reverse Split, will be proportionately increased by the factor of the ratio of the Reverse Split. For example,
if the Board of Directors determines to effect the Reverse Split at a ratio of 1-for-7, then the initial per share conversion
of our Series E Preferred Stock would increase to $21.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
contains approximate information relating to our common stock, assuming the Reverse Split is effected at a ratio of 1-for-7 and
based on share information as of the close of business on April 30, 2016:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Common Stock</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Pre-Reverse Split</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Post-Reverse Split<font style="font-family: Times New Roman, Times, Serif"><sup>(2)</sup></font></b></P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 64%">Outstanding</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">236,930,485&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">33,847,213&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -11pt; padding-left: 11pt">Reserved for issuance under outstanding options and available for issuance under our stock incentive plans</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">39,561,165&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">5,561,595&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Reserved for and available for issuance under our 2010 Employee Stock Purchase Plan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">1,408,659&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">201,237&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Reserved for issuance upon exercise of outstanding warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">273,280&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">39,040&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Reserved for issuance upon conversion of our outstanding Series E Preferred Stock<sup>(1)</sup></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">45,745,760&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: right">6,535,109&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 22.5pt"><SUP>(1)</SUP></TD><TD STYLE="text-align: justify">The Series E Preferred Stock is convertible into a number of shares of our common stock determined
by dividing the liquidation preference of $25.00 per share by the conversion price, currently $3.00 per share (or $21.00 assuming
a 1-for-7 Reverse Split ratio). If all outstanding Series E Preferred Stock were converted at the $3.00 per share conversion price
(assuming no Reverse Split), the holders of Series E Preferred Stock would receive an aggregate of 13,145,333 shares of our common
stock. If all outstanding Series E Preferred Stock were converted at the $21.00 per share conversion price (assuming a assuming
a 1-for-7 Reverse Split ratio), the holders of Series E Preferred Stock would receive an aggregate of 1,877,905 shares of our common
stock. However, we have reserved the maximum number of shares of our common stock that could be issued upon a change of control
event assuming our shares of common stock are acquired for consideration of $0.855 per share or less (or $5.985 assuming a 1-for-7
Reverse Split ratio). In this scenario, each outstanding share of Series E Preferred Stock could be converted into 29 shares of
our common stock (or approximately 4 shares of our common stock assuming a 1-for-7 Reverse Split ratio), representing the Share
Cap.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 9pt"></TD><TD STYLE="width: 22.5pt"><SUP>(2)</SUP></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Excludes the effect of the issuance of whole shares of common stock
in lieu of any fractional shares to which any stockholders would otherwise be entitled as a result of the Reverse Split, in accordance
with the procedures described below under &ldquo;Treatment of Fractional Shares&rdquo;.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>No Effect on Par Value</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we file the Amendment
and implement the proposed Reverse Split, the par value of our common stock will not be affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Effect on Registration and Stock Trading</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock
is currently registered under Section 12(b) of the Exchange Act and we are subject to the periodic reporting and other
requirements of the Exchange Act. The proposed Reverse Split will not affect the registration of our common stock under the
Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we implement the
proposed Reverse Split, our common stock will continue to trade on The NASDAQ Capital Market under the symbol &ldquo;PPHM&rdquo;.
However, our common stock would have a new CUSIP number, which is a number used to identify our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mechanics of Reverse Split</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If this Proposal No.
3 is approved by the stockholders at the Annual Meeting&nbsp;and our Board of Directors decides that it is in the best interests
of the Company and our stockholders to effectuate the Reverse Split (i.e., we have not otherwise regained compliance with NASDAQ&rsquo;s
minimum bid requirement), our stockholders will be notified&nbsp;that the Reverse Split has been effected. &nbsp;The mechanics
of the Reverse Split will differ depending upon&nbsp;whether a stockholder holds its shares in brokerage accounts or &ldquo;street
name&rdquo; or whether the shares are registered directly in a stockholder&rsquo;s name and held in book-entry form or certificate
form.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="width: 91%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Our
stockholders who hold shares in &ldquo;street name&rdquo; through a nominee (such as a bank or broker) will be treated in the
same manner as stockholders whose shares are registered in their names, and nominees will be instructed to effect the Reverse
Split for their beneficial holders. However, nominees may have different procedures for processing the Reverse Split and stockholders
holding shares in &ldquo;street name&rdquo; are encouraged to contact their nominees.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Our
    registered stockholders may hold some or all of their shares electronically in book-entry form under the direct registration
    system for securities. These stockholders will not have stock certificates evidencing their ownership of our common
    stock.&nbsp;&nbsp;They are, however, provided with a statement reflecting the number of shares registered in their
    accounts.&nbsp;&nbsp;Stockholders holding registered shares of our common stock in book-entry form need not take any action
    to receive post-Reverse Split shares as a transaction statement will automatically be sent to the stockholders address of
    record indicating the number of shares held.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Some of our registered stockholders
        hold all their shares in certificate form or a combination of certificate and book-entry form. Stockholders holding shares of common
        stock in certificate form will receive a transmittal letter from Broadrige Corporate Issuer Solutions, Inc. (the &ldquo;Transfer
        Agent&rdquo;) as soon as practicable after the Effective Date of the Reverse Split for use in transmitting the existing certificates
        representing shares of our common stock (the &ldquo;Old Certificates&rdquo;) to our Transfer Agent. The letter of transmittal will
        contain instructions for the surrender of the Old Certificates to our Transfer Agent in exchange for new certificates representing
        the appropriate number of whole shares of new common stock giving effect to the Reverse Split. No new stock certificates will be
        issued to any stockholder until such stockholder has surrendered all certificates, together with a properly completed and executed
        letter of transmittal, to our Transfer Agent. The stockholders will then receive, at their option, either a new certificate or
        certificates or book-entry shares representing the number of whole shares of common stock into which their pre-Reverse Split shares
        have been converted as a result of the Reverse Split. Until surrendered, the Company will deem outstanding Old Certificates held
        by stockholders to be cancelled and only to represent the number of whole shares of post-Reverse Split common stock to which the
        stockholders are entitled. STOCKHOLDERS SHOULD NOT DESTROY ANY STOCK CERTIFICATE(S) AND SHOULD NOT SUBMIT ANY CERTIFICATE(S) UNTIL
        REQUESTED TO DO SO.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 1.5in 0 0; text-align: justify">&nbsp;</P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Treatment of Fractional Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No fractional shares
of common stock would be issued as a result of the proposed Reverse Split. Instead, in the event the Reverse Split results in any
stockholder being entitled to receive fractional shares that, when aggregated, equal less than a whole share of common stock, such
fractional shares will be reclassified and converted from and after the Effective Time into one whole share of common stock in
lieu of such fractional shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For example, if the
Board of Directors determines to effect the Reverse Split at a ratio of 1-for-7, then a stockholder who holds fifty (50) shares
on a pre-split basis would hold eight (8) whole shares on a post-split basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Accounting Consequences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Reverse Split will
not affect the common stock capital account on our balance sheet. However, because the par value of our common stock
will remain unchanged as of the Effective Time, the components that comprise the common stock capital account will change by offsetting
amounts. Specifically, on our balance sheet, the common stock value would be adjusted downward commensurate with the
ratio of the Reverse Split, such that the common stock value would become an amount equal to the aggregate par value of the shares
of post-Reverse Split common stock. The additional paid-in capital amount recorded on our balance sheet would be increased
by an amount equal to the amount by which the common stock was decreased. Additionally, net loss per share would increase
proportionately as a result of the Reverse Split since there would be fewer shares outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>No Dissenter&rsquo;s Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Delaware
General Corporation Law, stockholders will not be entitled to dissenter&rsquo;s rights with respect to the proposed Amendment to
effect the Reverse Split, and the Company does not intend to independently provide stockholders with any such right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Federal Income Tax Consequences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is
a summary of certain material United States federal income tax consequences of the Reverse Split that we anticipate would
affect our stockholders.&nbsp;This discussion is based on the provisions of the Internal Revenue Code of 1986, as amended
(the &ldquo;Code&rdquo;), final, temporary and proposed U.S. Treasury regulations promulgated thereunder and current
administrative rulings and judicial decisions, all as in effect as of the date hereof. This summary is provided for your
general information only and does not address all aspects of the possible federal income tax consequences of the Reverse
Split and <B>IS NOT INTENDED AS TAX ADVICE TO ANY PERSON</B>. In particular, this summary does not consider the federal
income tax consequences to our stockholders in light of their individual investment circumstances or to holders subject to
special treatment under the federal income tax laws, and does not address any consequences of the Reverse Split under any
state, local or foreign tax laws. Moreover, this description does not address the U.S. federal estate and gift tax,
alternative minimum tax, or other tax consequences of the Reverse Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>ACCORDINGLY, YOU
MUST CONSULT WITH YOUR TAX ADVISOR REGARDING THE SPECIFIC TAX CONSEQUENCES OF THE REVERSE SPLIT TO YOU, INCLUDING THE APPLICATION
AND EFFECT OF FEDERAL, STATE, LOCAL AND FOREIGN INCOME AND OTHER TAX LAWS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, there
can be no assurance that the Internal Revenue Service (&ldquo;IRS&rdquo;) will not take a contrary position to the tax consequences
described herein or that such position will be sustained by a court. In addition, U.S. tax laws are subject to change, possibly
with retroactive effect, which may result in U.S. federal income tax considerations different from those summarized below. No ruling
from the IRS has been obtained with respect to the U.S. federal income tax consequences of the Reverse Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the
reverse stock split should qualify as a &ldquo;recapitalization&rdquo; for U.S. federal income tax purposes. Accordingly, a stockholder
should not recognize any gain or loss as a result of the Reverse Split. A stockholder&rsquo;s aggregate tax basis in its post-Reverse
Split shares of common stock to be received should be the same as the aggregate tax basis in the pre-Reverse Split shares of common
stock to be exchanged therefor.&nbsp;&nbsp;The holding period for the post-Reverse Split shares of common stock received should
include the period during which such stockholder held the pre-Reverse Split shares of common stock surrendered therefor, provided
all such common stock was held as a capital asset at the Effective Time. Stockholders should consult their tax advisors as to application
of the foregoing rules where shares of our common stock were acquired at different times or at different prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will not
recognize any gain or loss for accounting or tax purposes as a result of the Reverse Split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our beliefs regarding
the tax consequences of the Reverse Split are not binding upon the IRS, federal, state or local courts, and there can be no assurance
that the IRS or the courts will concur with the positions expressed above. The state and local tax consequences of the
Reverse Split may vary significantly as to each stockholder, depending on where he or she resides.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Consequences if the Reverse Split is Not Approved</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If this Proposal No.
3 is not approved, we may be unable to maintain the listing of our common stock on The NASDAQ Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recommendation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THE BOARD OF
DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE <FONT STYLE="font-size: 10pt"><U>FOR</U></FONT> THE PROPOSAL TO APPROVE THE
AMENDMENT TO OUR CERTIFICATE OF INCORPORATION, AS AMENDED, TO AUTHORIZE THE BOARD OF DIRECTORS TO EFFECT A REVERSE STOCK
SPLIT, IN ITS DISCRETION OF UP TO 1-FOR-7, SUBJECT TO THE BOARD OF DIRECTORS&rsquo; DISCRETION TO ABANDON SUCH AMENDMENT. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: blue; border-bottom: Black 0.5pt solid"><FONT STYLE="font-variant: small-caps; color: White"><B>Proposal
No. 4:</B></FONT><BR>
<FONT STYLE="font-variant: small-caps; color: white"><B>Approval of an Amendment to our 2010 Employee Stock Purchase Plan </B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Introduction</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are asking our stockholders
to approve an amendment to the Company&rsquo;s 2010 Employee Stock Purchase Plan to increase the number of shares of our common
stock subject to the 2010 Employee Stock Purchase Plan by 10,000,000 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s
2010 Employee Stock Purchase Plan, which is referred to herein as the &ldquo;ESPP&rdquo;, was originally approved by the Board
of Directors in August 2010 and the Company&rsquo;s stockholders in October 2010. A total of up to 5,000,000 shares of our common
stock were initially authorized for issuance under the ESPP. On April 22, 2016, subject to stockholder approval, the Board of Directors
approved a proposal to amend the ESPP to increase the number of shares of our common stock subject to the ESPP by 10,000,000 shares
(as so amended, the &ldquo;Amended ESPP&rdquo;) to up to 15,000,000 shares. (All share numbers in this section are before the proposed
Reverse Split described in Proposal No. 3 above.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose of the
Amended ESPP is to provide a means by which employees of the Company may be given an opportunity to purchase shares of  our
common stock through payroll deductions on a voluntary basis, to assist us in retaining the services of our employees, in recruiting
new employees and to provide incentives for such persons, which align the interest of our participants with those of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The rights to purchase
shares of our common stock under the Amended ESPP are intended to qualify as options issued under an &ldquo;employee stock purchase
plan&rdquo; as that term is defined in Section 423(b) of the Internal Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-style: normal"><B>Description
of the Amended ESPP</B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-style: normal"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A summary of the Amended
ESPP is set forth below, and the full text of the amendment to the ESPP is attached hereto as <U>Exhibit B</U>. The following discussion
is qualified in its entirety by reference to the amendment attached hereto as <U>Exhibit B</U> and the original text of the Amended
ESPP filed as Exhibit B to the Company&rsquo;s Definitive Proxy Statement on Schedule 14A, as filed with the SEC on August 27,
2010. Capitalized terms used below shall have the meanings ascribed to them in the Amended ESPP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Administration</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Amended ESPP will
be administered by the Board of Directors or a committee of the Board of Directors. The Board of Directors or such committee has
the authority to interpret the Amended ESPP, construe terms, adopt rules and regulations, prescribe forms, and make all determinations
under the Amended ESPP. If a participant is a member of the committee administering the Amended ESPP, that person may not decide
any matter relating to his or her participation in the Amended ESPP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Shares Available and Limitations on Share Issuances</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The total number of
shares of common stock originally authorized for issuance under the ESPP was 5,000,000 shares. At August 12, 2016, we had 1,408,659
shares of common stock that remained available for issuance under the ESPP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the current
number of employees participating in the ESPP, we believe such number of shares available for issuance under the ESPP will be fully
exhausted by April 30, 2017. Therefore, in order to continue to maintain an appropriate number of shares for issuance under the
ESPP, our Board of Directors is requesting that our stockholders approve the issuance of up to an additional 10,000,000 shares
of common stock under the ESPP. Consequently, if this proposal for the amendment of the ESPP is approved by stockholders, the Amended
ESPP will authorize the issuance of up to 15,000,000 shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares reserved
under the ESPP are subject to appropriate adjustment in the case of any extraordinary dividend or other distribution, recapitalization,
forward or reverse split, reorganization, merger, consolidation, spin-off, combination, repurchase, share exchange, or other similar
corporate transaction or event affecting our common stock. Shares purchased from the Company will be either authorized but unissued
shares, treasury shares or shares purchased on the open market. If any right to purchase shares of common stock terminates for
any reason, without having been exercised, then the shares of common stock not purchased under such right will again become available
for issuance under the Amended ESPP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise determined
by the Board of Directors or the committee of the Board of Directors administering the Amended ESPP, during any single offering
period, a participant may not purchase more than the largest number of whole shares determined by dividing (1) the product of $2,083
times the number of full months in the offering period by (2) the fair market value on the first day of the offering period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Eligibility</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, the employees
of the Company and its subsidiaries who are customarily employed by the Company or its subsidiaries for more than 20 hours per
week and for more than five months in a calendar year, who have been employed for at least three months prior to enrolling in the
Amended ESPP and who are employed on the first day of the applicable offering period are eligible to participate in the Amended
ESPP; except that no employee will be granted an option under the Amended ESPP if such employee would, immediately after the grant,
own 5% or more of the total combined voting power or value of all outstanding shares of all classes of securities of the Company
or any subsidiary. In addition, no participant shall be granted options to purchase shares having a fair market value greater than
$25,000 in any calendar year. As of July 31, 2016, 282 employees were eligible to participate in the Amended ESPP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Offering Periods and Enrollment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Amended ESPP provides
for two six-month offering periods per year during which payroll deductions will be made and held for the purchase of shares under
the Amended ESPP. The first offering period begins on the first trading day on or after each November 1; the second offering period
begins on the first trading day on or after each May 1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An eligible employee
may become a participant in the Amended ESPP by completing and delivering an enrollment agreement to the Company (or its designee),
or by following an electronic or other enrollment process determined by the Board of Directors (or a committee of the Board of
Directors) prior to the beginning of the offering period to which it relates. The enrollment agreement will authorize the payroll
deductions, which must be an amount not less than 2% nor more than 15% (or such higher or lower rates as the Board of Directors
may later specify) of such employee&rsquo;s &ldquo;eligible compensation&rdquo;, although an employee&rsquo;s contributions may
be reduced to the extent necessary to ensure that he or she will not purchase shares having a fair market value greater than $25,000
in any calendar year. The contribution rate elected by a participant will continue in effect until modified by the participant.
All employee contributions will be made by means of direct payroll deduction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After initial enrollment
in the Amended ESPP, the employee will be automatically re-enrolled in the Amended ESPP for subsequent offering periods unless
he or she files a notice of withdrawal, terminates employment, or otherwise become ineligible to participate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the purposes of
the Amended ESPP, the term &ldquo;eligible compensation&rdquo; includes base salary, overtime pay, and any retroactive base pay
adjustments to his or her annual base salary. Eligible compensation does not include any other compensation including but not limited
to, fringe benefits (including car allowances and relocation payments), employee discounts, stock-based compensation, bonuses,
commissions (unless such commissions are an integral, recurring part of compensation), income from stock option exercises, expense
reimbursements or allowances, long-term disability payments, workmen&rsquo;s compensation payments, welfare benefits, and any contributions
that the Company or a designated subsidiary makes to any benefit plan (including any 401(k) plan, or any other welfare or retirement
plan).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Purchase Price</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purchase price
per share at which shares of our common stock are sold in an offering period will be equal to the lesser of 85% of the fair market
value of our common stock (i) on the first trading day of the offering period or (ii) on the last trading day of the offering period.
As of August 12, 2016, the closing price of our common stock was $0.3698 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Purchase of Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The contributions of
each participant will be credited to an account maintained on behalf of such participant. On the last trading date of each offering
period, each option is exercised automatically and each participant&rsquo;s accumulated payroll deductions will be applied to the
purchase of whole shares of Company common stock, up to the maximum number of shares permitted under the Amended ESPP in a given
offering period. Any amounts remaining credited to a participant&rsquo;s account on the last trading day of the offering period
shall be refunded as soon as practicable thereafter, except that any balance which is less than the purchase price of one share
of common stock will be carried forward into the employee&rsquo;s payroll deduction account for the subsequent offering, unless
the employee elects not to participate in the subsequent offering, in which case, the balance in the employee&rsquo;s account shall
be refunded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Participants will have
the exclusive right to vote or direct the voting of shares once the shares are purchased and transferred into the participant&rsquo;s
name on the Company&rsquo;s books and records. Participants&rsquo; rights under the Amended ESPP are nontransferable except pursuant
to the laws of descent and distribution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Withdrawal from the Amended ESPP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a participant wishes
to cease participation in the Amended ESPP, the participant must deliver a withdrawal notice to the Company (or its designee) in
such form prescribed by the Company at any time prior to the date specified by the Committee, or if no such date is specified,
at least five business days prior to the last trading day of such offering period. Enrollment will also terminate upon termination
of a participant&rsquo;s employment by the Company and its subsidiaries. Upon termination of enrollment, cash amounts resulting
from previous payroll contributions will be repaid to the participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Amended ESPP Costs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company will pay
costs and expenses incurred in the administration of the Amended ESPP and maintenance of accounts, and will pay brokerage fees
and commissions for purchases. The Company will not pay brokerage fees and expenses relating to sales by participants, and participants
may be charged reasonable fees for withdrawals of share certificates and other specified services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the Company or its
stockholders enter into an agreement to dispose of all or substantially all of the assets or outstanding capital stock of the Company
by means of a sale, merger or reorganization in which the Company will not be the surviving corporation (other than a reorganization
effected primarily to change the State in which the Company is incorporated, a merger or consolidation with a wholly-owned Subsidiary,
or any other transaction in which there is no substantial change in the stockholders of the Company or their relative stock holdings,
regardless of whether the Company is the surviving corporation) or if the Company is liquidated, then all outstanding options under
the Amended ESPP shall automatically be exercised immediately prior to the consummation of such sale, merger, reorganization or
liquidation (deemed the end of the offering period in such case) at the purchase price described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Amendment and Termination</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board of Directors
may amend, alter, suspend, discontinue, or terminate the Amended ESPP without further stockholder approval, except stockholder
approval must be obtained within one year after the such action if stockholder approval is required by law or regulation or under
the rules of any automated quotation system or securities exchange (such as the NASDAQ) on which our common stock is then quoted
or listed, or if such stockholder approval is necessary in order for the Amended ESPP to continue to meet the requirements of Section
423 of the Code. The Amended ESPP will continue until terminated by action of the Board of Directors, although as noted above,
the number of shares authorized under the Amended ESPP is limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Federal Income Tax Consequences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following generally
summarizes the United States federal income tax consequences that will arise with respect to participation in the Amended ESPP
and with respect to the sale of shares of our common stock acquired under the Amended ESPP. This summary is based on the tax laws
in effect as of the date of this proxy statement. Rights to purchase shares under the Amended ESPP are intended to constitute &ldquo;options&rdquo;
issued pursuant to an &ldquo;employee stock purchase plan&rdquo; within the meaning of Section 423 of the Code. Changes to these
laws could alter the tax consequences described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&#9;No taxable income
results to the participants upon the grant of a right to purchase or upon the purchase of shares for his or her account under the
Amended ESPP (although the amount of a participant&rsquo;s payroll contributions under the Amended ESPP will be taxable as ordinary
income to the participant).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&#9;If the participant
disposes of shares less than two years after the first day of an offering period with respect to which he or she purchased the
shares, the participant will realize ordinary income in an amount equal to the fair market value of the shares on the date of purchase
minus the amount of the participant&rsquo;s payroll deductions used to purchase the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&#9;If the participant
holds the shares for at least two years after the first day of an offering period with respect to which he or she purchased the
shares, at the time the participant disposes of the shares he or she will realize ordinary income in an amount equal to the lesser
of (i) the purchase price discount as of the first day of the offering period (i.e., 15% of the fair market value of the shares
on the first day of the offering period) with respect to the purchased shares, and (ii) the fair market value of the shares on
the date of disposition minus the amount of the participant&rsquo;s payroll deductions used to purchase the shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&#9;In addition,
the participant will realize a long-term or short-term capital gain or loss, as the case may be, in an amount equal to the difference
between the amount realized upon any sale of the stock and the participant&rsquo;s basis in the stock (i.e., the purchase price
plus the amount, if any, taxed to the participant as ordinary income, as described in (2) and (3) above).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5)&#9;If the statutory
holding period described in (2) and (3) above is satisfied, the Company will not receive any deduction for federal income tax purposes
with respect to any discount in the sale price of stock applicable to such participant. If such statutory holding period is not
satisfied, the Company generally should be entitled to a tax deduction in an amount equal to the amount taxed to the participant
as ordinary income. Any such deduction will be subject to the limitations of Section&nbsp;162(m) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing provides
only a general description of the application of federal income tax laws to the Amended ESPP. The summary does not address the
effects of other federal taxes or taxes imposed under state, local, or foreign tax laws. Because of the complexities of the tax
laws, participants are encouraged to consult a tax advisor as to their individual circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Plan Benefits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Participation in the
Amended ESPP is voluntary and each eligible employee will make his or her own decision whether and to what extent to participate
in the plan. It is therefore not possible to determine the benefits or amounts that will be received in the future by individual
employees or groups of employees under the Amended ESPP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth, for each of the individuals and the various groups indicated, the total number of shares of our common stock that have
been purchased under the ESPP since its approval by our stockholders in October 2010 through April 29, 2016 (the last purchase
date under the ESPP):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Name and Position</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 73%; text-align: left">Steven W. King, President and Chief Executive Officer</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">68,314</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Paul J. Lytle, Chief Financial Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">67,815</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Shelley P.M. Fussey, Ph.D., Vice President, Intellectual Property</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">96,447</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Joseph S. Shan, Vice President, Clinical &amp; Regulatory Affairs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,683</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Mark R. Ziebell, Vice President, General Counsel and Corporate Secretary</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">All current executive officers as a group</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">243,259</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">All employees, including all current officers who are not executive officers, as a group</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,348,082</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Recommendation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THE BOARD OF DIRECTORS
UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE <FONT STYLE="font-size: 10pt"><U>FOR</U></FONT> THE APPROVAL OF THE AMENDMENT TO
THE 2010 EMPLOYEE STOCK PURCHASE PLAN.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: blue; border-bottom: Black 0.5pt solid"><FONT STYLE="font-variant: small-caps; color: White"><B>Proposal
No. 5:<BR>
Advisory Vote On Executive Compensation (&ldquo;Say-On-Pay&rdquo;)</B></FONT><B><FONT STYLE="font-variant: small-caps"> </FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Background</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Dodd-Frank Wall
Street Reform and Consumer Protection Act (the &ldquo;Dodd-Frank Act&rdquo;) requires that stockholders have the opportunity to
cast an advisory (non-binding) vote on executive compensation (a so-called &ldquo;say-on-pay&rdquo; vote), as well as an advisory
vote with respect to whether future say-on-pay votes will be held every one, two or three years (a so-called &ldquo;say-on-frequency&rdquo;
vote). At the 2011 Annual Meeting, a majority of stockholders present and entitled to vote on the proposal&nbsp;selected one year
as the desired frequency of future stockholder say-on-pay votes with respect to the say-on-frequency proposal. As such, the Board
of Directors adopted a resolution to hold &ldquo;say-on-pay&rdquo; votes annually. Since 2011, a majority of stockholders present
and entitled to vote on the proposal have approved the say-on-pay proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As described in detail
under the heading &ldquo;Compensation Discussion and Analysis,&rdquo; our executive compensation programs are designed to attract,
motivate and retain our named executive officers (our &ldquo;NEOs&rdquo;), who are critical to our success. Under these programs,
our NEOs are rewarded for the achievement of both specific financial and strategic goals, which are expected to result in increased
stockholder value. Please read the &ldquo;Compensation Discussion and Analysis&rdquo; and the tables and narrative that follow
for additional details about our executive compensation programs, including information about the fiscal year ended April 30, 2016
compensation of our NEOs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation
Committee regularly reviews the compensation programs for our NEOs, including with the assistance of its independent compensation
consultant, to ensure that they achieve the desired goals of aligning our executive compensation structure with our stockholders&rsquo;
interests and with current market practices. This includes establishing target goals and objectives based on our strategic and
operating plans. We closely monitor the compensation programs and pay levels of executives from other peer pharmaceutical and biopharmaceutical
companies of similar size, stage of development and complexity, so that we may ensure that our compensation programs are within
the norm of market practices. This enables us to retain our executive officers in a competitive market for executive talent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our
executive compensation programs have been effective at motivating the achievement of positive results, appropriately aligning pay
and performance, and enabling us to attract and retain talented executives within our industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Recommendation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We request stockholder
approval of our compensation of our NEOs for the fiscal year ended April 30, 2016 as disclosed in this Proxy Statement pursuant
to the SEC&rsquo;s compensation disclosure rules (which disclosure includes the &ldquo;Compensation Discussion and Analysis&rdquo;,
the compensation tables, and the narrative disclosures that accompany the compensation tables within the Executive Compensation
section of this Proxy Statement). This vote is not intended to address any specific item of compensation, but rather the overall
compensation of our NEOs and the philosophy, policies and practices described in this Proxy Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, we ask
that you vote &ldquo;FOR&rdquo; the following resolution at our 2016 Annual Meeting:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-align: justify">&ldquo;RESOLVED, that the stockholders
of Peregrine Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) approve, on an advisory basis, the compensation of the named executive
officers, as disclosed in the Company&rsquo;s Proxy Statement for the 2016 Annual Meeting of Stockholders pursuant to the compensation
disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis, the fiscal year
2016 Summary Compensation Table and the other related tables and disclosure within the Executive Compensation section of this Proxy
Statement.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.95pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The vote solicited
for Proposal No. 5 is advisory, and therefore is not binding on the Company, our Board of Directors or our Compensation Committee,
nor will its outcome require the Company, our Board of Directors or our Compensation Committee to take any action. Moreover, the
outcome of the vote will not be construed as overruling any decision by the Company, the Board of Directors or the Compensation
Committee. However, our Compensation Committee, which is responsible for designing and administering our executive compensation
programs, values the opinions expressed by our stockholders in their vote on this Proposal and will consider the outcome of this
vote when making future compensation decisions for our NEOs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THE BOARD OF DIRECTORS
UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE <FONT STYLE="font-size: 10pt"><U>FOR</U></FONT> THE PROPOSAL TO APPROVE, ON AN ADVISORY
BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THIS PROXY STATEMENT.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: blue; border-top: Black 0.5pt solid; border-bottom: Black 0.5pt solid"><FONT STYLE="font-variant: small-caps; color: White"><B>Security
Ownership Of Certain Beneficial Owners, Directors And Management</B></FONT><B><FONT STYLE="font-variant: small-caps"> </FONT></B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Share Ownership</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth certain information regarding the beneficial ownership of our common stock as of August 12, 2016, by: (i)&nbsp;each
stockholder known to us to beneficially own more than 5% of our common stock; (ii) each director and director nominee; (iii)&nbsp;our
Named Executive Officers for the fiscal year ended April 30, 2016; and (iv)&nbsp;all directors and executive officers of the Company
as a group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beneficial ownership
is determined in accordance with the rules of the SEC and includes voting or investment power with respect to shares of common
stock. Under these rules, shares of common stock subject to any option, warrant or right that are exercisable or convertible within
60 days of August 12, 2016, and shares of common stock that could be acquired through the conversion of our outstanding  Series
E Preferred Stock are deemed beneficially owned and outstanding for computing
the percentage ownership of the individual or entity holding such securities, but are not considered outstanding for computing
the percentage ownership of any other person. Unless otherwise indicated, each person named below holds sole investment and voting
power, other than the powers that may be shared with the person&rsquo;s spouse under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><BR CLEAR="ALL">
</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Beneficial Ownership of </b></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Common Stock</b></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Name and Address of Beneficial Owner</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percent (a)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold">5% Stockholders:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0">Eastern Capital Limited (b)</P>
                                             <P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 22pt">  10 Market Street, #773 <BR>Grand Cayman, KY1-9006 Cayman Islands</P></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">30,106,945</TD><TD STYLE="width: 4%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: center">12.28%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="font-weight: bold; text-align: left">Named Executive Officers and Directors (c):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Steven W. King</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,620,100</TD><TD STYLE="text-align: left">(d)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">1.07%</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Eric S. Swartz</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,346,307</TD><TD STYLE="text-align: left">(d)(e)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Carlton M. Johnson, Jr.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,681,848</TD><TD STYLE="text-align: left">(d)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">David H. Pohl</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,676,189</TD><TD STYLE="text-align: left">(d)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Paul J. Lytle</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,385,366</TD><TD STYLE="text-align: left">(d)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Joseph S. Shan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">887,369</TD><TD STYLE="text-align: left">(d)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Shelley P.M. Fussey, Ph.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">844,100</TD><TD STYLE="text-align: left">(d)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">*</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Mark R. Ziebell</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">813,750</TD><TD STYLE="padding-bottom: 1pt; text-align: left">(d)(f)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">*</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">All directors and executive officers as a group (8&nbsp;persons)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,255,029</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: center">4.85%</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">_________________</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><P STYLE="margin-top: 0; margin-bottom: 0"></P>
                                                        <P STYLE="margin-top: 0; margin-bottom: 0">*</P></TD><TD STYLE="text-align: justify">Represents
                                         less than 1% of the outstanding shares of our common stock.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">(a)</TD>
    <TD STYLE="text-align: justify">Applicable
percentage ownership of common stock computed on the basis of 241,456,721 shares of common stock outstanding at August 12, 2016,
plus (i) shares of our common stock that could be acquired through the exercise of stock options that will become exercisable
within 60 days of August 12, 2016 and (ii) shares of our common stock that could be acquired upon conversion of shares of our
Series E Preferred Stock.</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">The information set forth
                                         herein is based solely on a Schedule 13G/A filed with the SEC on November 2, 2015 by
                                         Eastern Capital Limited. The number of beneficial shares owned includes 3,666,667 shares
                                         of common stock that could be acquired upon conversion of the 440,000 shares of Series
                                         E Preferred Stock held by Eastern Capital Limited. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">The address of all of our
                                         executive officers and directors is c/o Peregrine Pharmaceuticals, Inc., 14282 Franklin
                                         Avenue, Tustin, California, 92780.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">Includes shares that such
                                         individuals have the right to acquire as of August 12, 2016, or within 60&nbsp;days thereafter,
                                         pursuant to outstanding stock options as follows: Mr. King&mdash;2,426,137 shares; Mr.
                                         Swartz&mdash;1,674,189 shares; Mr. Johnson&mdash;1,674,189 shares; Mr. Pohl&mdash;1,674,189;
                                         Mr. Lytle&mdash;1,272,500 shares; Mr. Shan&mdash;866,250 shares; Dr. Fussey&mdash;733,625
                                         shares; and Mr. Ziebell&mdash;806,250 shares. Such shares are deemed to be outstanding
                                         in calculating the percentage ownership of such individual (and the group), but are not
                                         deemed to be outstanding as to any other person.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">(e)</TD>
    <TD STYLE="text-align: justify">Includes
107,739 shares of common stock owned by Swartz Ventures, Inc., 126,000 shares of common stock owned by Highlight Fund, LLC,
and 52,978 shares held in an Individual Retirement Account (&ldquo;IRA&rdquo;) for the benefit of Mr. Swartz. Mr. Swartz has sole
control over Swartz Ventures, Inc., Highlight Fund, LLC and his IRA.</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify">Includes 7,500 shares of
                                         common stock that could be acquired upon conversion of the 900 shares of Series E Preferred
                                         Stock held by Mr. Ziebell.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Section 16(a) Beneficial Ownership Reporting Compliance</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section&nbsp;16(a)
of the Exchange Act requires our executive officers and directors, and persons who own more than 10% of a registered class of our
equity securities (&ldquo;Reporting Persons&rdquo;), to file reports of ownership and changes in ownership with the SEC and with
The NASDAQ Stock Market. Reporting Persons are required by SEC regulations to furnish us with copies of all forms they file pursuant
to Section&nbsp;16(a). Based solely on our review of the copies of such reports we received, and written representations from certain
Reporting Persons that no other reports were required for those persons, to the best of our knowledge, we believe that during the
year ended April 30, 2016, each of the Reporting Persons met all applicable Section&nbsp;16(a) filing requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: blue; border-top: Black 0.5pt solid; border-bottom: Black 0.5pt solid"><FONT STYLE="font-variant: small-caps; color: White"><B>COMPENSATION
DISCUSSION AND ANALYSIS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Introduction</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Compensation Committee is responsible for establishing, implementing and overseeing our overall compensation strategy and policies,
including our executive compensation program, in a manner that supports our business objectives.</FONT> The Compensation Committee&rsquo;s
complete roles and responsibilities are set forth in a written charter of the Compensation Committee adopted by our Board of Directors,
which can be found at our website, www.peregrineinc.com<I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I></I></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Compensation Discussion
and Analysis explains our compensation philosophy, policies and practices for the fiscal year ended April 30, 2016 for the following
executive officers, who are referred to in this Compensation Discussion and Analysis and the subsequent tables as our &ldquo;Named
Executive Officers&rdquo; or &ldquo;NEOs&rdquo;:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Steven W. King, President and Chief Executive Officer;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Paul J. Lytle, Chief Financial Officer;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Shelley P.M. Fussey, Ph.D., Vice President, Intellectual Property;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Joseph S. Shan, Vice President, Clinical &amp; Regulatory Affairs; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Mark R. Ziebell, Vice President, General Counsel and Corporate Secretary.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Executive compensation
programs affect all employees by setting general levels of compensation and helping to create an environment of goals, rewards
and expectations. Because we believe the performance of every employee is important to our success, we are mindful of the effect
executive compensation and incentive programs have on all of our employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The employment market
for personnel and executives with experience in the biotechnology and pharmaceutical industry in Southern California is very competitive
because there are several pharmaceutical, biotechnology and medical device companies in that region. The majority of our competitors
in this geographic area have more resources than we do which makes it more difficult for us to hire and retain key personnel. As
a result, the Compensation Committee must establish compensation packages that will enable the Company to be competitive with the
local market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Given the competitive
environment in which we operate, o<FONT STYLE="font-family: Times New Roman, Times, Serif">ur executive compensation programs are
designed to deliver compensation that is competitive with our peer group and that allows us to attract and retain superior talent
who can perform effectively and succeed in a demanding business environment. Our compensation programs are also designed to reward
performance against pre-established corporate and individual goals and align the interests of our executives with our stockholders.
We believe that the compensation of our executive officers should focus executive behavior on the achievement of near-term corporate
targets as well as long-term business objectives and strategies. We believe that pay-for-performance compensation programs, which
reward our executives when they achieve individual and/or corporate goals, create stockholder value and thus have emphasized company
and individual performance in setting compensation. We use a combination of base salary, annual cash incentive compensation programs,
a long-term equity incentive compensation program and a broad-based benefits program to create a competitive compensation package
for our executive management team.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our President and Chief
Executive Officer, who attends most meetings of the Compensation Committee, assists the Compensation Committee in determining the
compensation of all other executive officers by, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">recommending to the Compensation Committee appropriate base salaries of the other executive officers;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">establishing annual individual performance objectives for the other executive officers and evaluating
their performance against such objectives;&nbsp;and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">making recommendations, from time to time, for annual or special stock grants or stock option grants
(e.g., for motivational or retention purposes) to other executive officers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The other executive officers
do not have a role in determining their own compensation, other than discussing their annual individual performance objectives
with the President and Chief Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Independent Compensation
Consultants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee
has the authority to directly retain the services of independent consultants and other experts to assist in fulfilling its responsibilities.
For the fiscal year ended April 30, 2016, the Compensation Committee engaged Barney &amp; Barney LLC, or Barney &amp; Barney, <FONT STYLE="font-family: Times New Roman, Times, Serif">to
review our executive compensation programs and to assess our executive officers&rsquo; base salaries, short-term incentive opportunities,
target and actual total cash, long-term incentive value and total direct compensation from a competitive standpoint. As described
herein, Barney &amp; Barney assisted the Compensation Committee in defining the appropriate market of our peer companies for executive
compensation and practices and in benchmarking our executive compensation program against the peer group. The Compensation Committee
has adopted a compensation philosophy of targeting our executive compensation to the 50<SUP>th</SUP> percentile of executive compensation
of our peer group. Executive compensation may be above or below the 50<SUP>th</SUP> percentile based on an executive&rsquo;s experience,
scope of position, individual performance and Company constraints.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee
uses the information it obtains from Barney &amp; Barney primarily for evaluating our executive compensation practices, including
measuring the competitiveness of our practices. The Compensation Committee also uses the information obtained from Barney &amp;
Barney to review our cash bonus policy, equity awards, and base salary benchmarks across all levels of the Company. The Compensation
Committee has assessed the independence of Barney &amp; Barney pursuant to SEC rules and the corporate governance rules of The
NASDAQ Stock Market and concluded that no conflict of interest exists that would prevent Barney &amp; Barney from independently
advising the Compensation Committee. In compliance with the SEC and the corporate governance rules of The NASDAQ Stock Market,
Barney &amp; Barney provided the Compensation Committee with a letter addressing each of the six independence factors described
in those rules. Their responses affirm the independence of Barney &amp; Barney and its employees who service the Compensation Committee
on executive compensation matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Components of Our Executive Compensation Program</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The primary elements
of our executive compensation program are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">base salary;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">annual cash bonus plan;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">equity awards;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">employment agreements and severance and change-in-control benefits; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.7pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">perquisites and other benefits.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee
has structured our executive compensation program to ensure that executive officers are compensated in a manner consistent with
stockholder interests, competitive pay practices and applicable regulatory requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee
does not have any formal or informal policy or target for allocating compensation between long-term and short-term compensation
or between cash and non-cash compensation. Instead, the Compensation Committee, after reviewing information provided by an independent
compensation consulting firm, determines subjectively what it believes to be the appropriate level and mix of the various compensation
components that it believes appropriate to achieve the compensation and corporate objectives described in this discussion.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Base Salary</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Base salary is used
to recognize the experience, skills, knowledge and responsibilities required of all our employees, including our executives, and
to provide a fixed amount of compensation for performing daily responsibilities, and also provide stability and security. When
reviewing base salaries for the fiscal year ended April 30, 2016, the Compensation Committee considered various data regarding
the base salaries of executive officers in comparable positions at other biotechnology companies. Additional factors included,
but were not limited to, company size, market capitalization, stage of development of a company&rsquo;s products and geographic
location. The Compensation Committee also considered the individual experience level and actual performance of each executive officer
in light of our needs and objectives. The Compensation Committee also reviewed an analysis from Barney &amp; Barney, our independent
compensation consulting firm, to ensure that base salaries are competitive and within the competitive range of other biotechnology
companies in our peer group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Base salaries are reviewed
at least annually by the Compensation Committee, and may be adjusted to realign salaries with market levels after taking into account
individual responsibilities, performance and experience, subject to minimum salary requirements set forth in applicable employment
agreements. Base salaries may be increased for merit reasons, based on the executive&rsquo;s success in meeting or exceeding individual
performance objectives as well as our combined success in meeting corporate goals, including biomanufacturing revenue goals and
research and development goals. An executive&rsquo;s base salary is also evaluated by reviewing the executive&rsquo;s other compensation
components to ensure that the executive&rsquo;s total compensation is in line with our overall compensation philosophy as discussed
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following annual
base salary amounts of our Named Executive Officers for the fiscal year ended April 30, 2016 were determined based on the &ldquo;Factors
for Determining Compensation&rdquo;, as noted below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Named Executive Officer</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Annual Base <BR>
Salary<BR>
 ($)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 43%; text-align: left">Steven W. King</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 13%; text-align: center">520,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Paul J. Lytle</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">390,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Shelley P.M. Fussey, Ph.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">321,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Joseph S. Shan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">300,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Mark R. Ziebell</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">348,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal">The
above salaries for fiscal year ended April 30, 2016 were the same as the base salaries for fiscal year ended April 30, 2015, as
the Compensation Committee did not authorize an increase in executive base salaries for fiscal year ended April 30, 2016.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Annual Cash Bonus Plan</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2011, the Compensation
Committee adopted and approved a formal Annual Cash Bonus Plan (the &ldquo;Bonus Plan&rdquo;) for its Named Executive Officers
for the fiscal year ended April 30, 2012 performance and for each subsequent fiscal year, unless amended, which the Compensation
Committee used to determine the annual bonuses awarded to Named Executive Officers. The Compensation Committee may also make discretionary
bonuses outside of the framework of the Bonus Plan, but in general, each participant&rsquo;s annual cash bonus under the Bonus
Plan will be determined by multiplying the participant&rsquo;s annual base salary for the applicable fiscal year by (a) a corporate
goal achievement percentage ranging from 0% to 100%, (b) a target bonus percentage for such participant, generally targeted for
the 50<SUP>th</SUP> percentile of our peer groups, and (c) a corporate factor ranging from 0 to 1.5, based on the Company&rsquo;s
achievement of corporate goals, the participant&rsquo;s achievement of individual goals, the participant&rsquo;s role and responsibilities
within the Company, and other factors as determined by the Compensation Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&rsquo;s
corporate goals are set at or around the beginning of each fiscal year by the Compensation Committee, based on recommendations
by the Company&rsquo;s management. At the end of each fiscal year, the Compensation Committee determines the extent to which the
corporate goals were achieved (expressed as a percentage) and each participant&rsquo;s corporate factor based on a quantitative
and qualitative review of such participant&rsquo;s performance, in addition to other factors determined by the Compensation Committee.
Each participant&rsquo;s individual goals, which are aligned to support the corporate goals, are also set at or around the beginning
of each fiscal year and are also evaluated based on a quantitative and qualitative review of performance. The Compensation Committee&rsquo;s
chair will recommend the CEO&rsquo;s individual goals and individual factor to the Compensation Committee and the CEO will recommend
other executive officers individual goals and individual factors to the Compensation Committee. All individual goals and individual
factors will be set by the Compensation Committee. Corporate goals and individual goals may be modified by the Compensation Committee
during the applicable fiscal year based on operational and financial developments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the fiscal year
ended April 30, 2016, the Compensation Committee established the following corporate goals:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="background-color: #D9D9D9">
    <td style="width: 84%; border: Black 1pt solid; text-align: center; text-indent: 1.2pt"><font style="font-size: 10pt"><b>Goal</b></font></td>
    <td style="width: 16%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; text-indent: 0in"><font style="font-size: 10pt"><b>Weighting</b></font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; text-indent: 1.2pt"><font style="font-size: 10pt">Prepare bavituximab for commercial production</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; text-indent: 1.9pt"><font style="font-size: 10pt">20%</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; text-indent: 1.2pt"><font style="font-size: 10pt">Achieve in excess of $33,000,000 in third-party contract manufacturing revenue</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; text-indent: 1.9pt"><font style="font-size: 10pt">25%</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; text-indent: 1.2pt"><font style="font-size: 10pt">Complete enrollment in the SUNRISE Phase III clinical trial</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; text-indent: 1.9pt"><font style="font-size: 10pt">10%</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; text-indent: 0in"><font style="font-size: 10pt">Advance the scientific knowledge of bavituximab through multiple publications or presentations</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; text-indent: 1.9pt"><font style="font-size: 10pt">5%</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; text-indent: 0in"><font style="font-size: 10pt">Advance bavituximab through immuno-oncology collaborations</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; text-indent: 1.9pt"><font style="font-size: 10pt">15%</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; text-indent: 0in"><font style="font-size: 10pt">Partner bavituximab for ex-United States territories</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; text-indent: 1.9pt"><font style="font-size: 10pt">15%</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; text-indent: 0in"><font style="font-size: 10pt">Other financial goals focused on funding our operations</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; text-indent: 1.9pt"><font style="font-size: 10pt">10%</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the end of
the fiscal year, the Compensation Committee reviews performance relative to each corporate goal and determines the achievement
level of each corporate goal, and then calculates an overall aggregate achievement percentage (not to exceed 100%) which takes
into consideration the individual weighting attributed to each corporate goal. The Compensation Committee does not use a strict
formula in assessing the Company&rsquo;s level of achievement with respect to each goal, but rather considers factors such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the level of success achieved for each corporate goal;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the difficulty of the goal;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">whether significant unforeseen events or obstacles reasonably beyond our control impacted the Company&rsquo;s
ability to achieve the goal, or altered the expected difficulty of the goal;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">changes in circumstances which may have made the goal more or less important to our near- and long-term
success; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 49.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">other corporate accomplishments during the fiscal year that, while not established as a formal
goal, are nonetheless deemed important to our near- and long-term success and enhance stockholder value.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the Compensation
Committee&rsquo;s review of our performance during fiscal year 2016 relative to our corporate goals, it was determined that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the corporate goal to partner bavituximab for ex-United States territories was not achieved, and
as a result the Compensation Committee assigned a zero achievement percentage;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the goals related to third-party contract manufacturing revenue and scientific publications and/or
presentations were achieved above 100% because the goals were significantly exceeded; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">each of the other goals was achieved at 100%.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, the Compensation
Committee determined that the aggregate achievement percentage with respect to our corporate goals for the fiscal year ended April
30, 2016 was 105%, which was then reduced to the Bonus Plan maximum of 100%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While the Compensation
Committee determined that 100% of the corporate goals for the fiscal year ended April 30, 2016 had been achieved based on the above
analysis, the Compensation Committee decided to reduce each executive&rsquo;s discretionary corporate factor by 25% due to the
Company&rsquo;s discontinuance of the Phase III SUNRISE trial in February 2016 and to redirect the 25% opportunity to specific
new corporate goals to be achieved in fiscal year 2017 which the Compensation Committee believes will help build stockholder value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth the target bonus percentage, based upon the &ldquo;Factors for Determining Compensation&rdquo;, as noted below, of our
Named Executive Officers approved by the Compensation Committee for the fiscal year ended April 30, 2016 and their respective earned
cash bonuses as approved by the Compensation Committee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Named Executive Officer</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fiscal Year 2016 Target</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 10pt"><b>Fiscal Year 2016 Bonus ($)</b></font><b><sup>(1)</sup></b></P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 46%; text-align: left">Steven W. King</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">60%</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">312,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Paul J. Lytle</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">156,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Shelley P.M. Fussey, Ph.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,175</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Joseph S. Shan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Mark R. Ziebell</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35%</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">91,350</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">______________</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">The corporate factors for the Named Executive Officers, after the 25% reduction by the Compensation
Committee described above, were as follows: Mr. King and Mr. Lytle, 1.00; Dr. Fussey, 0.50; Mr. Shan, 0.60; and Mr. Ziebel, 0.75.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition,
with respect to annual bonuses for the fiscal year ended April 30, 2015, the Compensation Committee had  determined that a
portion of the annual bonus to be awarded for the fiscal year ended April 30, 2015 for Mr. King and Mr. Shan should not be
paid and should be made subject to the attainment of an additional performance milestone related to a bavituximab clinical
trial collaboration. The amount carried over was $50,000 for Mr. King and $59,917 for Mr. Shan. This additional
performance milestone was subsequently achieved, and as a result, these bonus amounts for Mr. King and Mr. Shan carried over
from the fiscal year ended April 30, 2015 were earned and paid during this past fiscal year. Accordingly, these amounts are
included in the Summary Compensation Table as &ldquo;Non-Equity Incentive Plan Compensation&rdquo; for the fiscal year ended
April 30, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Equity Awards</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Stock Option Awards
and Grant Practices.</I> Based on market practice and our objective to align executives&rsquo; interest with those of our stockholders,
we currently use stock option awards as the primary form of long-term incentive compensation for executives and other employees.
In the fiscal year ended April 30, 2012, the Compensation Committee implemented a policy of a routine annual broad-based grant
of stock option awards to our executive officers and other employees, with the grant typically occurring during the initial weeks
of our fiscal year. The grant date of such annual award and of other grants (i.e., for new hires) is either on the date the Compensation
Committee approves the grants or on a pre-selected later date, such as a future hire date. In determining the size and types of
equity grants to executive officers, the Compensation Committee considers, among other things, comparative industry data provided
by the Compensation Committee&rsquo;s independent compensation consultant, our outstanding shares at the time of grant, the number
and type of equity awards granted to such individuals in prior years, the equity available under our long-term incentive plan and
desirable run rate and aggregate estimated equity usage in the future, each executive officer&rsquo;s ownership in our Company,
our corporate performance, and each executive officer&rsquo;s individual performance, role and responsibilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee
exercises discretion in determining the information it considers, as well as any weighting of particular information, in determining
the equity awards. The determination of equity awards is made by the Compensation Committee after evaluating the information and
areas of consideration described above in their totality. For the fiscal year ended April 30, 2016, our annual broad-based stock
option grant was approved by the Compensation Committee on May 11, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock option grant
information for the fiscal year ended April 30, 2016, is set forth below under &ldquo;Grants of Plan-Based Awards For the Fiscal
Year Ended April 30, 2016.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Stock Awards and
Award Practices.</I><B> </B>In addition to stock options, we have in the past used stock awards as a form of long-term incentive
compensation for executives and other employees. Stock awards are shares of common stock that vest in accordance with the terms
established by the Compensation Committee. Usually, the awards will be subject to vesting upon the Company&rsquo;s timely attainment
of certain predetermined clinical, financial or operational milestones with specific targeted attainment dates or vest over a specific
predetermined period of performance. However, the Compensation Committee, at its discretion, may issue discretionary stock awards
that are not subject to any future vesting requirements. There were no discretionary stock award grants to our Named Executive
Officers during the fiscal year ended April 30, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Employment Agreements, Severance
and Change-in-Control Benefits</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have employment
agreements with all of our Named Executive Officers providing for severance payments and accelerated vesting benefits triggered
by various termination events. For a description of these agreements and our potential payment obligations, please see &ldquo;Overview
of Employment Agreements and Potential Payments Upon Termination or Change-in-Control&rdquo; and the related tabular disclosure
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">When entering into
employment agreements which provide for post-termination compensation for our Named Executive Officers, the Compensation Committee
considers, among multiple factors, peer company practice, retention needs and consistency of post-termination compensation among
our executives. Gains from prior equity awards are not a material consideration in setting the level of such compensation. In particular,
we believe such employment agreements benefit us and our stockholders by attracting and retaining executives in a marketplace where
such protections are commonly offered by our peer companies. We also believe that severance protection triggered by a change-in-control
allows our executives to assess a potential change-in-control objectively, from the perspective of what is best for our stockholders,
without regard to the potential impact of the transaction on their own job security. We use a &ldquo;double trigger&rdquo; with
respect to benefits that are to be provided in connection with a change-in-control. A change-in-control does not itself trigger
benefits; rather, benefits are paid only if the employment of the executive is terminated by us other than for cause or due to
the executive&rsquo;s death or disability during a specified period before or after a change of control. We believe a &ldquo;double
trigger&rdquo; benefit maximizes stockholder value because it prevents a windfall to executives in the event of a change of control
in which the executive retains significant responsibility as defined in his or her individual agreement, while still providing
our executives appropriate incentives to cooperate in negotiating any change of control that may put their jobs at risk. Further,
we believe the severance protection offered under the employment agreements is balanced with the interests of the Company and its
stockholders, as the executives are bound by non-disclosure, non-competition, and non-solicitation arrangements and must execute
a general release in favor of the Company as a condition to receiving benefits under these agreements. None of the agreements include
any tax gross-up payments for &ldquo;golden parachute&rdquo; excise taxes. All of the Named Executive Officers are &ldquo;at will&rdquo;
employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These employment agreements
are subject to automatic one-year extensions annually and, as part of the Compensation Committee&rsquo;s review of all of our executive
compensation practices, will be reviewed to ensure that they continue to serve our interests in retaining these key executives,
remain consistent with packages offered by our peers, and provide reasonable levels of severance protection and compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Perquisites and Other Benefits</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain broad-based
benefits that are provided to all employees, including health, dental, and vision insurance, life and disability insurance, a 401(k)
plan, and an Employee Stock Purchase Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the 401(k) plan,
Named Executive Officers are allowed to contribute on the same basis as other employees of the Company as determined by IRS regulations.
Effective January 1, 2010, the Company voluntarily agreed to match 50% of all employee contributions, including Named Executive
Officers, up to the first 6% of a participant&rsquo;s annual salary for all 401(k) plan contributions, subject to certain IRS limitations.
In addition, the plan allows for additional discretionary matching contributions in excess of the 50% match. During calendar year
2015, the Company voluntarily agreed to match 50% of all employee contributions (for employees with up to five years of service),
75% of all employee contributions (for employees with six to nine years of service), and 100% of all employee contributions (for
employees with ten or more years of service), including Named Executive Officers, up to the first 6% of a participant&rsquo;s annual
salary for all 401(k) plan contributions. Under the 401(k) plan, each participating employee, including Named Executive Officers,
is fully vested in his or her contributions to the 401(k) plan and Company contributions to the 401(k) plan will fully vest after
six years of service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Employee
Stock Purchase Plan, Named Executive Officers are allowed to participate on the same basis as other employees of the Company, which
allows employees on a voluntarily basis to purchase shares of our common stock directly from the Company through accumulated payroll
deductions, which the Company believes closely aligns the interests of participants with the interests of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, Named
Executive Officers are eligible to participate in the same employee benefit plans as all other employees. The cost of health and
dental insurance was 100% covered by the Company for Named Executive Officers during the fiscal year ended April 30, 2016. In addition,
all employees, including Named Executive Officers, receive one (1) times their annual salary in term-life insurance, long-term
disability benefits, and vision insurance at no cost to the employee. We also provide all employees, including Named Executive
Officers, the option to make pre-tax payroll deductions up to $2,550 per year under a flexible spending account plan that can be
utilized for out-of-pocket medical, dental and other allowable expenses. The Company also provides paid-time-off benefits to cover
vacation and sick time and annually determined Company holidays.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Factors for Determining Compensation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Performance<B>.</B></I>
One of the primary objectives of our compensation program is to motivate our Named Executive Officers to achieve our short and
long-term strategic goals. These goals are tied to, among other things, increasing contract manufacturing revenue, the advancement
of our product pipeline, the attainment of clinical and regulatory milestones, the development, acquisition and out-licensing of
key technologies, and the securing of capital funding. In addition to linking compensation to the attainment of pre-approved goals,
individual performance is assessed on the basis of more subjective, non-formulaic, criteria, such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">involvement in, and responsibility for, the development and implementation
of our strategic plans and the attainment of our strategic and operating objectives; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">participation in the achievement of contract manufacturing revenue
growth and/or strategic or regulatory milestones; </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">contribution to the management team and application of managerial
leadership skills; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">involvement in accessing capital to fund our research and development
operations, facilities expansion and improvements and other business activities. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&ldquo;Say-on-Pay&rdquo;
Consideration</I>. <FONT STYLE="font-family: Times New Roman, Times, Serif"> At our 2015 Annual Meeting, approximately 57% of the
shares voted at the meeting approved, on an advisory basis, the compensation of our Named Executive Officers. Given that less than
70% of the shares voted to approve the &lsquo;say-on-pay&rsquo; advisory proposal, the Compensation Committee spent additional
time with its independent compensation consultant, reviewing the Company&rsquo;s compensation practices, analyzing the various
elements of executive compensation for each Named Executive Officer and how such elements compare to the median compensation for
the Company&rsquo;s peer group</FONT>, assessing the Company&rsquo;s progress towards the attainment of corporate goals, and other
factors affecting the Company&rsquo;s strategic objectives<FONT STYLE="font-family: Times New Roman, Times, Serif">. Following
thoughtful deliberation, the Compensation Committee determined not to implement specific changes and continued with its compensation
philosophy and its balanced approach to various components of its compensation program, after giving consideration to the level
of attainment of corporate goals and benchmarking compensation with the Company&rsquo;s peer group</FONT>; however, while not a
specific corporate goal for the fiscal year ended April 30, 2016, the Compensation Committee did take into consideration the impact
of the February 2016 decision to discontinue the SUNRISE Phase III trial on the Company&rsquo;s long-term product development plans
and its effect on stockholder value and determined to reduce each executive&rsquo;s discretionary corporate factor by 25% (as described
above)<FONT STYLE="font-family: Times New Roman, Times, Serif">. Furthermore, the Compensation Committee does monitor the results
of the annual advisory &lsquo;say-on-pay&rsquo; proposal and refers to such results as one of many factors considered, along with
peer group benchmarking, in connection with the discharge of its responsibilities, although the Compensation Committee does not
assign a quantitative weighting to any such factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Market Benchmarks
and Competitive Analysis.</I> We believe that our select peer group provides useful information to help us establish competitive
compensation practices and levels of compensation that allow us to attract, retain and motivate a talented executive team and,
at the same time, aligns the interests of our executives with those of our stockholders. Accordingly, in the fiscal year ended
April 30, 2016, Barney &amp; Barney, the independent compensation consultant engaged by the Compensation Committee with experience
in evaluating public biopharmaceutical companies, has helped the Compensation Committee collect and analyze data and to compare
all components of our compensation program, including base salary, annual cash bonus and long-term equity awards, to the practices
of peer companies. In the fiscal year ended April 30, 2016, Barney &amp; Barney developed a list of peer group of pharmaceutical
and biopharmaceutical companies based on several characteristics, including, being publicly traded, relative company size (e.g.,
market capitalization and number of employees), stage of development, performance and geographic location as compared to peer companies,
as well as the specific responsibilities of our executives. In addition, this peer group also includes companies with which we
believe we must compete for talent. The Compensation Committee intends to review and modify this peer group periodically to ensure
that this list remains aligned with our size and stage of development. For the fiscal year ended April 30, 2016, our peer group
consisted of the following 23 companies:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.5in">
<tr>
    <TD STYLE="width: 32%; text-align: justify; text-indent: 0in">Amicus Therapeutics, Inc.</td>
    <TD STYLE="width: 32%; text-align: justify; text-indent: 0in">Dynavax Technologies Corp.</td>
    <TD STYLE="width: 32%; text-align: justify; text-indent: 0in">Sarepta Therapeutics, Inc.</td></tr>
<tr>
    <TD STYLE="text-align: justify; text-indent: 0in">Anika Therapeutics, Inc.</td>
    <TD STYLE="text-align: justify; text-indent: 0in">Endocyte, Inc.</td>
    <TD STYLE="text-align: justify; text-indent: 0in">Spectrum Pharmaceuticals, Inc.</td></tr>
<tr>
    <TD STYLE="text-align: justify; text-indent: 0in">ArQule, Inc.</td>
    <TD STYLE="text-align: justify; text-indent: 0in">Geron Corporation</td>
    <TD STYLE="text-align: justify; text-indent: 0in">Sucampo Pharmaceuticals, Inc.</td></tr>
<tr>
    <TD STYLE="text-align: justify; text-indent: 0in">Array BioPharma Inc.</td>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in">Immunomedics, Inc.</td>
    <TD STYLE="text-align: justify; text-indent: 0in">Synta Pharmaceuticals, Inc.</td></tr>
<tr>
    <TD STYLE="text-align: justify; text-indent: 0in">ChemoCentryx, Inc.</td>
    <TD STYLE="vertical-align: top; text-align: justify; text-indent: 0in">Infinity Pharmaceuticals, Inc.</td>
    <TD STYLE="text-align: justify; text-indent: 0in">Threshold Pharmaceuticals, Inc.</td></tr>
<tr>
    <TD STYLE="text-align: justify; text-indent: 0in">Chimerix, Inc.</td>
    <TD STYLE="text-align: justify; text-indent: 0in">MacroGenics, Inc.</td>
    <TD STYLE="text-align: justify; text-indent: 0in">XOMA Corporation</td></tr>
<tr>
    <TD STYLE="text-align: justify; text-indent: 0in">CTI BioPharma Corp.</td>
    <TD STYLE="text-align: justify; text-indent: 0in">NewLink Genetics Corporation</td>
    <TD STYLE="text-align: justify; text-indent: 0in">Zogenix, Inc.</td></tr>
<tr>
    <TD STYLE="text-align: justify; text-indent: 0in">Cytokinetics, Inc.</td>
    <TD STYLE="text-align: justify; text-indent: 0in">Rigel Pharmaceuticals, Inc.</td>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The executive employment
market in the biotechnology and pharmaceutical industry in Southern California is very competitive because there are many pharmaceutical,
biotechnology and medical device companies in that region, many of which are similar to us in size and stage of development. We
believe our executive compensation must be competitive within such a peer group, yet fully aligned with our current stage of development
and our responsibilities to stockholders. Our general philosophy and practice is to target each of our executive&rsquo;s overall
compensation to be at approximately the market median for our peer group. This benchmarking indicated that the total direct compensation
for our President and Chief Executive Officer, Chief Financial Officer and General Counsel for the fiscal year ended April 30,
2016 was below the 25<SUP>th</SUP> percentile of our peer group, and the other two Named Executive Officers were either slightly
below the 50<SUP>th</SUP> percentile or slightly above the 75<SUP>th</SUP> percentile. The Compensation Committee considered this
benchmarking information as one consideration in making the compensation decisions reflected above, primarily to determine whether
compensation paid to Named Executive Officers, in light of Company and individual performance, is at, above or below the median
of executive compensation among the Company&rsquo;s peer group.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Compensation Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of its oversight
of our compensation policies, the Compensation Committee considers the incentives created by our executive compensation program
and the impact that our compensation policies could have on our overall risk profile. In addition, the Compensation Committee annually
reviews our compensation policies and procedures to determine whether they create risks that are reasonably likely to have a material
adverse effect on the Company. Based on its latest review, the Compensation Committee has concluded that our compensation policies
and procedures do not create such risks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Summary</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee
believes the Company&rsquo;s compensation programs are designed and administered in a manner consistent with its compensation philosophy
and objectives. The Compensation Committee monitors these programs in recognition of the dynamic marketplace in which the Company
competes for talent. The Compensation Committee intends to continue to emphasize pay-for-performance and equity-based incentive
programs that reward executives for actual results and that are consistent with stockholder interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: blue; border-top: Black 0.5pt solid; border-bottom: Black 0.5pt solid"><FONT STYLE="font-variant: small-caps; color: White"><B>EXECUTIVE
COMPENSATION</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Executive Officers</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth information regarding our current executive officers as of April 30, 2016:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Executive Officer</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center">Age</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Position</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 30%; text-align: left">Steven W. King</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 8%; text-align: center">52</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 56%; text-align: left">President and Chief Executive Officer, Director</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Paul J. Lytle</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">48</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Shelley P.M. Fussey, Ph.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Vice President, Intellectual Property</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Joseph S. Shan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">43</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Vice President, Clinical &amp; Regulatory Affairs</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Mark R. Ziebell</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">52</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Vice President, General Counsel and Corporate Secretary</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following biographies
describe the business experience of our executive officers. For the biography of Mr.&nbsp;King, see &ldquo;Proposal No. 1: Election
of Directors&rdquo; above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Paul J. Lytle</I>
has served as Chief Financial Officer since August 2002 and has over 20 years of finance and accounting experience. Mr. Lytle oversees
various functions, including finance and accounting, financial reporting, corporate governance, investor relations, human resources
and information technology. Mr. Lytle started with us in March 1997 as Corporate Controller and has held positions of increasing
responsibility with us. Mr. Lytle was promoted to Vice President of Finance and Accounting and was elected as our Corporate Secretary
from 2000 through July 2012. Prior to joining us, Mr. Lytle worked for Deloitte LLP. Mr. Lytle holds a B.S. in Business Administration
from the California State University at Long Beach and is a certified public accountant in the State of California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Shelley P.M. Fussey,
Ph.D.</I> has served as our Vice President, Intellectual Property since February 2005. Dr. Fussey plays a key role in our U.S.
and international patenting, patent analysis and patent defense. Dr. Fussey&rsquo;s expertise includes patent strategy for technologies
developed both in-house and in-licensed from universities. She has broad experience in intellectual property consulting for areas
including cancer treatment, immunology, and antiviral technology, as well as other areas central to pharmaceutical and biotechnology
drug development. Prior to joining us, Dr. Fussey worked for the law firms of Williams, Morgan &amp; Amerson and Arnold, White
and Durkee. She holds a Ph.D. in Biochemistry and a B.Sc. in Biochemistry with First Class Honours (Summa Cum Laude) from the University
of Newcastle upon Tyne, U.K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Joseph S. Shan</I>
has served as Vice President, Clinical &amp; Regulatory Affairs since March 2009 and has served as our head of Clinical and Regulatory
Affairs since January 2003. He is responsible for the design and execution of our clinical trials and overseeing regulatory submissions.
Since joining us in 2000, Mr. Shan has been instrumental in advancing the clinical development of our lead immunotherapy candidate,
bavituximab. Prior to joining us, Mr. Shan held positions of increasing responsibility in clinical and regulatory affairs at Edwards
Lifesciences (formerly Baxter Healthcare Corporation) and Sulzer Medica. Mr. Shan received his B.S. degree in Physiological Sciences
from the University of California, Los Angeles and his M.P.H. degree from the George Washington University in Washington, D.C.
He is a member of the American Society of Clinical Oncology, the Association of Clinical Research Professionals and the Regulatory
Affairs Professionals Society.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Mark R. Ziebell</I>
has served as Vice President, General Counsel since June 2012 and Corporate Secretary since July 2012, and has been practicing
corporate and securities law for over 20 years. Prior to joining us, Mr. Ziebell was a partner with the Costa Mesa, California
office of Snell &amp; Wilmer LLP where he worked from March 2004 to June 2012. Mr. Ziebell has represented public and private companies
in a wide range of corporate and securities matters, mergers and acquisitions, strategic alliance matters and corporate governance.
His experience involves a variety of industries, including biopharmaceutical and life sciences. Mr. Ziebell was our outside corporate
counsel from 1999 to June 2012. Mr. Ziebell earned his B.S. in accounting in 1986 from the University of San Francisco and his
Juris Doctorate in 1994 from the University of San Francisco School of Law. Prior to earning his law degree, Mr. Ziebell was a
certified public accountant with BDO Seidman in San Francisco, California.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Compensation Summary</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
contains information with respect to the compensation for the fiscal years ended April 30, 2016, 2015 and 2014 by each individual
who acted as our chief executive officer, our chief financial officer, and our three other most highly compensated executive officers
during the fiscal year ended April 30, 2016. We refer to the executive officers identified in this table as our &ldquo;Named Executive
Officers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SUMMARY COMPENSATION TABLE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24%; border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Name and Principal Position</P></TD>
    <TD STYLE="width: 7%; border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Fiscal Year</P></TD>
    <TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Salary<BR>
($)<SUP>(1)</SUP></P></TD>
    <TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Bonus</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">($)<SUP>(2)</SUP></P></TD>
    <TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Stock<BR>
 Awards<BR>
 ($)<SUP>(3)</SUP></P></TD>
    <TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Option<BR>
 Awards</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">($)<SUP>(3)</SUP></P></TD>
    <TD STYLE="width: 11%; border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Non-Equity<BR>
 Incentive Plan<BR>
 Compensation<BR>
 ($)<SUP>(4)</SUP></FONT></TD>
    <TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">All Other<BR>
 Compensation<BR>
 ($)<SUP>(5)</SUP></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; width: 3%; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: center; vertical-align: bottom">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Total ($)</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-size: 10pt">Steven W. King,</FONT></P>
                                <P STYLE="margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">President and Chief<BR>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executive Officer</FONT></P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2016</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2015</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2014</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">520,000</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">517,160</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">446,160</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&mdash;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&mdash;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">111,540</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&mdash;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&mdash;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">139,000</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">316,860</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">581,280</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">472,560</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">362,000&nbsp;&nbsp;&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">389,863&nbsp;&nbsp;&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">289,112&nbsp;&nbsp;&nbsp;</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">51,043</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">39,754</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">120,968</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed">&nbsp;<BR>
    <BR>
    <SUP>(6)</SUP></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">1,249,903</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">1,528,057</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">1,579,340</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt dashed; border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Paul J. Lytle,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer</P></TD>
    <TD STYLE="border-top: Black 1pt dashed; border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2016</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2015</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2014</P></TD>
    <TD STYLE="border-top: Black 1pt dashed; border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">390,000</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">388,032</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">338,844</P></TD>
    <TD STYLE="border-top: Black 1pt dashed; border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&mdash;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&mdash;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">84,711</P></TD>
    <TD STYLE="border-top: Black 1pt dashed; border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&mdash;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&mdash;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&mdash;</P></TD>
    <TD STYLE="border-top: Black 1pt dashed; border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">158,430</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">290,640</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">236,280</P></TD>
    <TD STYLE="border-top: Black 1pt dashed; border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">156,000&nbsp;&nbsp;&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">219,931&nbsp;&nbsp;&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">146,381&nbsp;&nbsp;&nbsp;</P></TD>
    <TD STYLE="border-top: Black 1pt dashed; border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">50,580</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">40,253</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">37,811</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt dashed; border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">755,010</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">938,856</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">844,027</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Shelley P.M. Fussey,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vice President, Intellectual<BR>

        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2016</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2015</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2014</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">321,000</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">319,874</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">291,720</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&mdash;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&mdash;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">72,930</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&mdash;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&mdash;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&mdash;</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">79,215</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">145,320</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">118,140</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">56,175&nbsp;&nbsp;&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">114,994&nbsp;&nbsp;&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">110,270&nbsp;&nbsp;&nbsp;</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">30,004</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">20,746</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">18,223</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">486,394</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">600,934</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">611,283</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Joseph S. Shan,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vice
President, Clinical &amp;<BR>
 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulatory Affairs</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2016</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2015</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2014</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">300,000</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">298,862</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">270,400</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&mdash;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&mdash;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">67,600</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&mdash;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&mdash;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&mdash;</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">105,620</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">145,320</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">118,140</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">122,917&nbsp;&nbsp;&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">59,917&nbsp;&nbsp;&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">68,141&nbsp;&nbsp;&nbsp;</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">50,463</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">38,468</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">39,551</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">579,000</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">542,567</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">563,832</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD STYLE="border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Mark
R. Ziebell,<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vice President, General<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Counsel and Corporate<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Secretary</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed; text-align: center; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 0pt; margin-left: 0">2016<BR>
2015<BR>
2014<BR>
</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed; text-align: left; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 0pt; margin-left: 0">348,000<BR>
346,731<BR>
315,000<BR>
</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 0pt; margin-left: 0; text-align: center">&mdash;<BR>
&mdash;<BR>
78,750</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 0pt; margin-left: 0; text-align: center">&mdash;<BR>
&mdash;<BR>
&mdash;</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 0pt; margin-left: 0; text-align: center">105,620<BR>
254,310<BR>
206,745</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 0pt; margin-left: 0; text-align: right">91,350&nbsp;&nbsp;&nbsp;<BR>
114,477&nbsp;&nbsp;&nbsp;<BR>
        109,148&nbsp;&nbsp;&nbsp;</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 0pt; margin-left: 0; text-align: right">42,334<BR>
40,575<BR>
37,772</P></TD>
    <TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt dashed">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-bottom: 0pt; margin-left: 0; text-align: right">587,304<BR>
756,093<BR>
747,415</P></TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">________________</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 90%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 5%">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD STYLE="text-align: justify; width: 85%">Salary information is reported as of the last payroll paid prior to or immediately after April 30th of each fiscal year.</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 90%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 5%">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD STYLE="text-align: justify; width: 95%">Represents a retention bonus award earned by the Named Executive Officer during the fiscal year ended April 30, 2014. As a result
of the uncertainty created within our corporate organization due to discovery of major discrepancies in connection with our Phase
IIb second-line NSCLC trial caused by a third party vendor, in order to ensure stability within our organization, the continued
employment of our Named Executive Officers and their continued efforts in pursuing our corporate goals and objectives, as well
as the completion of the detailed review of the Phase IIb trial (which ultimately led to promising final data), on December 27,
2012, the Compensation Committee approved the opportunity for each of our Named Executive Officers to earn a retention bonus equal
to twenty-five percent (25%) of his or her base salary for the fiscal year ended April 30, 2013 provided such Named Executive
Officer was continuously employed by us through December 31, 2013.</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 90%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 5%">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD>
    <TD STYLE="text-align: justify; width: 85%">Represents the aggregate grant date fair value of the awards made in each fiscal year as computed in accordance with the authoritative
guidance for share-based compensation. These amounts do not correspond to the actual value that may be recognized by each Named
Executive Officer. Additional information regarding outstanding awards, including corresponding exercise prices and expiration
dates, can be found in the &ldquo;Outstanding Equity Awards at Fiscal Year-End&rdquo; table of this Proxy Statement. The assumptions
used in determining the grant date fair values of the stock and option awards are set forth in Note&nbsp;6 &ldquo;Equity Compensation
Plans&rdquo; in our Annual Report on Form&nbsp;10-K for the period ended April 30, 2016, filed with the SEC on July 14, 2016.</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 90%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 5%">(4)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 85%">Represents performance bonuses earned under the Company&rsquo;s Annual Cash Bonus Plan. For Mr. King and Mr. Shan, includes an
additional amount related to the performance bonus for the fiscal year ended April 30, 2015 that was carried over and made subject
to an additional performance requirement that was achieved in the fiscal year ended April 30, 2016. Additional information regarding
the Company&rsquo;s Annual Cash Bonus Plan for its Named Executive Officers can be found in the &ldquo;Compensation Discussion
and Analysis&rdquo; section of this Proxy Statement under &ldquo;Annual Cash Bonus Plan&rdquo;.</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 90%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 5%">(5)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 85%">Except as described in footnote 6 below, amounts shown in this column reflect the cost of benefits paid on behalf of the Named
Executive Officer for health, dental, and vision benefits in addition to premiums paid for disability and term life insurance
(collectively referred to as &ldquo;Health Benefits&rdquo;) as well as company contributions to the Peregrine Pharmaceuticals,
Inc. 401(k) Plan. Health Benefits paid and/or accrued during the fiscal year ended April 30, 2016 for each Named Executive Officer
were as follows: Mr. King - $33,490; Mr. Lytle - $34,069; Dr. Fussey - $13,517; Mr. Shan - $33,952; and Mr. Ziebell - $34,015.
Company contributions to the Peregrine Pharmaceuticals, Inc. 401(k) Plan during the fiscal year ended April 30, 2016 for each
Named Executive Officer were as follows: Mr. King - $17,553; Mr. Lytle - $16,511; Dr. Fussey - $16,487; Mr. Shan - $16,511; and
Mr. Ziebell - $8,319.</TD></TR>
</TABLE>


<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 90%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 5%">(6)<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 85%">Includes tax gross-up payments of $83,685 to cover applicable statutory state and federal income and employment taxes based on
statutory withholding rates resulting from the vesting of a stock award granted during the fiscal year ended April 30, 2014. Subsequent
to the fiscal year ended April 30, 2014, the Compensation Committee of the Board of Directors approved a policy prohibiting the
tax gross-up of any payments to the Company&rsquo;s Named Executive Officers (unless the circumstances for any such tax gross-up
have been reviewed and approved by the Compensation Committee).</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Grants of Plan-Based Awards For the Fiscal Year Ended April
30, 2016</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
set forth certain summary information with respect to non-equity incentive plans and each plan-based award granted during the fiscal
year ended April 30, 2016 to our Named Executive Officers:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>GRANTS OF PLAN-BASED AWARDS FOR THE FISCAL
YEAR ENDED APRIL 30, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td nowrap>&nbsp;</td>
    <td nowrap>&nbsp;</td>
    <td nowrap>&nbsp;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Estimated Future Payouts</b></font><br>
<font style="font-size: 10pt"><b>Under Non-Equity Incentive</b></font><br>
<font style="font-size: 10pt"><b>Plan Awards (1)</b></font></td>
    <td nowrap>&nbsp;</td>
    <td nowrap>&nbsp;</td>
    <TD NOWRAP STYLE="text-align: center"><B>All Other<BR>
    Stock Awards:<BR>
    Number of<BR>
    Shares of</B></td>
    <TD NOWRAP STYLE="text-align: center"><B>&nbsp;</B></td>
    <TD NOWRAP STYLE="text-align: center"><B>All Other<BR>
    Option <BR>
    Awards: <BR>
    Number of<BR>
    Securities<BR>
    Underlying<BR>
    </B></td>
    <TD NOWRAP STYLE="text-align: center"><B>&nbsp;</B></td>
    <TD NOWRAP STYLE="text-align: center"><B>Exercise<BR>
    or Base<BR>
    Price of<BR>
    Option</B></td>
    <TD NOWRAP STYLE="text-align: center"><B>&nbsp;</B></td>
    <TD NOWRAP STYLE="text-align: center"><B>Grant Date <BR>
    Fair Value of<BR>
    Stock or <BR>
    Option</B></td></tr>
<TR STYLE="text-align: center; vertical-align: bottom">
    <td style="vertical-align: bottom; width: 21%; border-bottom: Black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Name</b></font></td>
    <td style="vertical-align: bottom; width: 9%; border-bottom: Black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Grant Date</b></font></td>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center">&nbsp;</td>
    <TD STYLE="vertical-align: bottom; width: 4%; border-bottom: Black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Threshold<BR>
 ($)</b></font></td>
    <TD STYLE="vertical-align: bottom; width: 7%; border-bottom: Black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Target <BR>
($)</b></font></td>
    <TD STYLE="vertical-align: bottom; width: 7%; border-bottom: Black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Maximum<BR>
 ($)</b></font></td>
    <td style="vertical-align: top; width: 2%">&nbsp;</td>
    <td nowrap style="vertical-align: top; width: 2%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Stock
or Units</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>(#)</B></FONT></td>
    <td nowrap style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: Black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Options</B><BR>
<B>(#) (2)</B></P></td>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 7%; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Awards</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>($/sh)</B></FONT></td>
    <td style="vertical-align: bottom; width: 2%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 11%; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Awards</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>($) (3)</B></FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <td nowrap><font style="font-size: 10pt">Steven W. King</font></td>
    <td nowrap style="text-align: right"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap>&nbsp;</td>
    <td nowrap style="text-align: center"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="text-align: center"><font style="font-size: 10pt">312,000</font></td>
    <td nowrap style="text-align: center"><font style="font-size: 10pt">468,000</font></td>
    <td nowrap>&nbsp;</td>
    <td nowrap>&nbsp;</td>
    <td nowrap style="text-align: center"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap>&nbsp;</td>
    <td nowrap style="text-align: right"><font style="font-size: 10pt">&mdash;&nbsp;&nbsp;</font></td>
    <td nowrap>&nbsp;</td>
    <td nowrap style="text-align: right"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap>&nbsp;</td>
    <td nowrap style="text-align: right"><font style="font-size: 10pt">&mdash;</font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <TD NOWRAP STYLE="border-bottom: Black 1pt dashed">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: right; border-bottom: Black 1pt dashed"><font style="font-size: 10pt">5/11/2015</font></td>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt dashed">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt dashed"><font style="font-size: 10pt">&mdash;</font></td>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt dashed"><font style="font-size: 10pt">&mdash;</font></td>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt dashed"><font style="font-size: 10pt">&mdash;</font></td>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt dashed">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt dashed">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt dashed"><font style="font-size: 10pt">&mdash;</font></td>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt dashed">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: right; border-bottom: Black 1pt dashed"><font style="font-size: 10pt">300,000&nbsp;&nbsp;</font></td>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt dashed">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: right; border-bottom: Black 1pt dashed"><font style="font-size: 10pt">1.31</font></td>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt dashed">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: right; border-bottom: Black 1pt dashed"><font style="font-size: 10pt">316,860</font></td></tr>
<tr style="vertical-align: top">
    <td nowrap><font style="font-size: 10pt">Paul J. Lytle</font></td>
    <td nowrap style="text-align: right"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap>&nbsp;</td>
    <td nowrap style="text-align: center"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="text-align: center"><font style="font-size: 10pt">156,000</font></td>
    <td nowrap style="text-align: center"><font style="font-size: 10pt">234,000</font></td>
    <td nowrap>&nbsp;</td>
    <td nowrap>&nbsp;</td>
    <td nowrap style="text-align: center"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap>&nbsp;</td>
    <td nowrap style="text-align: right"><font style="font-size: 10pt">&mdash;&nbsp;&nbsp;</font></td>
    <td nowrap style="text-align: center">&nbsp;</td>
    <td nowrap style="text-align: right"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="text-align: center">&nbsp;</td>
    <td nowrap style="text-align: right"><font style="font-size: 10pt">&mdash;</font></td></tr>
<tr style="vertical-align: top">
    <TD NOWRAP STYLE="border-bottom: Black 1pt dashed">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: right; border-bottom: Black 1pt dashed"><font style="font-size: 10pt">5/11/2015</font></td>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt dashed">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt dashed"><font style="font-size: 10pt">&mdash;</font></td>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt dashed"><font style="font-size: 10pt">&mdash;</font></td>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt dashed"><font style="font-size: 10pt">&mdash;</font></td>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt dashed">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt dashed">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt dashed"><font style="font-size: 10pt">&mdash;</font></td>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt dashed">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: right; border-bottom: Black 1pt dashed"><font style="font-size: 10pt">150,000 </font></td>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt dashed">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: right; border-bottom: Black 1pt dashed"><font style="font-size: 10pt">1.31</font></td>
    <TD NOWRAP STYLE="text-align: center; border-bottom: Black 1pt dashed">&nbsp;</td>
    <TD NOWRAP STYLE="text-align: right; border-bottom: Black 1pt dashed"><font style="font-size: 10pt">158,430</font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <td nowrap><font style="font-size: 10pt">Shelley P.M. Fussey</font></td>
    <td nowrap style="text-align: right"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="text-align: center">&nbsp;</td>
    <td nowrap style="text-align: center"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="text-align: center"><font style="font-size: 10pt">112,350</font></td>
    <td nowrap style="text-align: center"><font style="font-size: 10pt">168,525</font></td>
    <td nowrap style="text-align: center">&nbsp;</td>
    <td nowrap style="text-align: center">&nbsp;</td>
    <td nowrap style="text-align: center"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="text-align: center">&nbsp;</td>
    <td nowrap style="text-align: right"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="text-align: center">&nbsp;</td>
    <td nowrap style="text-align: right"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="text-align: center">&nbsp;</td>
    <td nowrap style="text-align: right"><font style="font-size: 10pt">&mdash;</font></td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(238,238,238)">
    <td nowrap>&nbsp;</td>
    <td nowrap style="text-align: right"><font style="font-size: 10pt">5/11/2015</font></td>
    <td nowrap style="text-align: center">&nbsp;</td>
    <td nowrap style="text-align: center"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="text-align: center"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="text-align: center"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="text-align: center">&nbsp;</td>
    <td nowrap style="text-align: center">&nbsp;</td>
    <td nowrap style="text-align: center"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="text-align: center">&nbsp;</td>
    <td nowrap style="text-align: right"><font style="font-size: 10pt">75,000 </font></td>
    <td nowrap style="text-align: center">&nbsp;</td>
    <td nowrap style="text-align: right"><font style="font-size: 10pt">1.31</font></td>
    <td nowrap style="text-align: center">&nbsp;</td>
    <td nowrap style="text-align: right"><font style="font-size: 10pt">79,215</font></td></tr>
<tr>
    <td nowrap style="vertical-align: bottom; border-top: Black 1pt dashed"><font style="font-size: 10pt">Joseph S. Shan</font></td>
    <td nowrap style="vertical-align: bottom; border-top: Black 1pt dashed; text-align: right"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="vertical-align: bottom; border-top: Black 1pt dashed; text-align: center">&nbsp;</td>
    <td nowrap style="vertical-align: bottom; border-top: Black 1pt dashed; text-align: center"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="vertical-align: bottom; border-top: Black 1pt dashed; text-align: center"><font style="font-size: 10pt">105,000</font></td>
    <td nowrap style="vertical-align: bottom; border-top: Black 1pt dashed; text-align: center"><font style="font-size: 10pt">157,500</font></td>
    <td nowrap style="vertical-align: bottom; border-top: Black 1pt dashed; text-align: center">&nbsp;</td>
    <td nowrap style="vertical-align: bottom; border-top: Black 1pt dashed; text-align: center">&nbsp;</td>
    <td nowrap style="vertical-align: top; border-top: Black 1pt dashed; text-align: center"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="vertical-align: bottom; border-top: Black 1pt dashed; text-align: center">&nbsp;</td>
    <td nowrap style="vertical-align: top; border-top: Black 1pt dashed; text-align: right"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="vertical-align: top; border-top: Black 1pt dashed; text-align: center">&nbsp;</td>
    <td nowrap style="vertical-align: top; border-top: Black 1pt dashed; text-align: right"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="vertical-align: top; border-top: Black 1pt dashed; text-align: center">&nbsp;</td>
    <td nowrap style="vertical-align: top; border-top: Black 1pt dashed; text-align: right"><font style="font-size: 10pt">&mdash;</font></td></tr>
<tr>
    <td nowrap style="vertical-align: bottom">&nbsp;</td>
    <td nowrap style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">5/11/2015</font></td>
    <td nowrap style="vertical-align: bottom; text-align: center">&nbsp;</td>
    <td nowrap style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="vertical-align: bottom; text-align: center"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="vertical-align: bottom; text-align: center">&nbsp;</td>
    <td nowrap style="vertical-align: bottom; text-align: center">&nbsp;</td>
    <td nowrap style="vertical-align: top; text-align: center"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="vertical-align: bottom; text-align: center">&nbsp;</td>
    <td nowrap style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">100,000 </font></td>
    <td nowrap style="vertical-align: bottom; text-align: center">&nbsp;</td>
    <td nowrap style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">1.31</font></td>
    <td nowrap style="vertical-align: bottom; text-align: center">&nbsp;</td>
    <td nowrap style="vertical-align: bottom; text-align: right"><font style="font-size: 10pt">105,620</font></td></tr>
<TR STYLE="background-color: rgb(238,238,238)">
    <td nowrap style="vertical-align: bottom; border-top: Black 1pt dashed"><font style="font-size: 10pt">Mark R. Ziebell</font></td>
    <td nowrap style="vertical-align: bottom; border-top: Black 1pt dashed; text-align: right"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="vertical-align: bottom; border-top: Black 1pt dashed; text-align: center">&nbsp;</td>
    <td nowrap style="vertical-align: bottom; border-top: Black 1pt dashed; text-align: center"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="vertical-align: bottom; border-top: Black 1pt dashed; text-align: center"><font style="font-size: 10pt">121,800</font></td>
    <td nowrap style="vertical-align: bottom; border-top: Black 1pt dashed; text-align: center"><font style="font-size: 10pt">182,700</font></td>
    <td nowrap style="vertical-align: bottom; border-top: Black 1pt dashed; text-align: center">&nbsp;</td>
    <td nowrap style="vertical-align: bottom; border-top: Black 1pt dashed; text-align: center">&nbsp;</td>
    <td nowrap style="vertical-align: top; border-top: Black 1pt dashed; text-align: center"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="vertical-align: bottom; border-top: Black 1pt dashed; text-align: center">&nbsp;</td>
    <td nowrap style="vertical-align: top; border-top: Black 1pt dashed; text-align: right"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="vertical-align: top; border-top: Black 1pt dashed; text-align: center">&nbsp;</td>
    <td nowrap style="vertical-align: top; border-top: Black 1pt dashed; text-align: right"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="vertical-align: top; border-top: Black 1pt dashed; text-align: center">&nbsp;</td>
    <td nowrap style="vertical-align: top; border-top: Black 1pt dashed; text-align: right"><font style="font-size: 10pt">&mdash;</font></td></tr>
<TR STYLE="background-color: rgb(238,238,238)">
    <td nowrap style="vertical-align: bottom; border-bottom: Black 1pt dashed">&nbsp;</td>
    <td nowrap style="vertical-align: bottom; border-bottom: Black 1pt dashed; text-align: right"><font style="font-size: 10pt">5/11/2015</font></td>
    <td nowrap style="vertical-align: bottom; border-bottom: Black 1pt dashed; text-align: center">&nbsp;</td>
    <td nowrap style="vertical-align: bottom; border-bottom: Black 1pt dashed; text-align: center"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="vertical-align: bottom; border-bottom: Black 1pt dashed; text-align: center"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="vertical-align: bottom; border-bottom: Black 1pt dashed; text-align: center"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="vertical-align: bottom; border-bottom: Black 1pt dashed; text-align: center">&nbsp;</td>
    <td nowrap style="vertical-align: bottom; border-bottom: Black 1pt dashed; text-align: center">&nbsp;</td>
    <td nowrap style="vertical-align: top; border-bottom: Black 1pt dashed; text-align: center"><font style="font-size: 10pt">&mdash;</font></td>
    <td nowrap style="vertical-align: bottom; border-bottom: Black 1pt dashed; text-align: center">&nbsp;</td>
    <td nowrap style="vertical-align: bottom; border-bottom: Black 1pt dashed; text-align: right"><font style="font-size: 10pt">100,000</font></td>
    <td nowrap style="vertical-align: bottom; border-bottom: Black 1pt dashed; text-align: center">&nbsp;</td>
    <td nowrap style="vertical-align: bottom; border-bottom: Black 1pt dashed; text-align: right"><font style="font-size: 10pt">1.31</font></td>
    <td nowrap style="vertical-align: bottom; border-bottom: Black 1pt dashed; text-align: center">&nbsp;</td>
    <td nowrap style="vertical-align: bottom; border-bottom: Black 1pt dashed; text-align: right"><font style="font-size: 10pt">105,620</font></td></tr>
</table>
<P STYLE="margin-top: 0; margin-bottom: 0">________________</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Represents each Named Executive Officer&rsquo;s participation in the Company&rsquo;s Annual Cash
Bonus Plan, as adopted by the Compensation Committee in July 2011. The amounts shown in the &ldquo;Target&rdquo; column reflect
a percentage of each Named Executive Officer&rsquo;s base salary for the fiscal year ended April 30, 2016, as specified under the
Annual Cash Bonus Plan. The amounts shown in the &ldquo;Maximum&rdquo; column are 150% of the respective target amounts, representing
the 1.5 times corporate multiplier under the Annual Cash Bonus Plan. There is no minimum amount payable for a certain level of
performance. Additional information regarding the Company&rsquo;s Annual Cash Bonus Plan for its Named Executive Officers can be
found in the &ldquo;Compensation Discussion and Analysis&rdquo; section of this Proxy Statement under &ldquo;Annual Cash Bonus
Plan&rdquo;. The actual amount of bonus earned by each Named Executive Officer under the Annual Cash Bonus Plan is reflected in
the Summary Compensation Table above under the heading, &ldquo;Non-Equity Incentive Plan Compensation.&rdquo;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Option awards referenced in the table above were granted under our 2011 Stock Incentive Plan and
vest in eight (8) equal quarterly installments over a two-year period beginning on the first quarter following the date of grant
and each quarter thereafter until fully-vested</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">The assumptions used in determining the grant date fair value of option awards are set forth in
Note&nbsp;6 &ldquo;Equity Compensation Plans&rdquo; in our Annual Report on Form&nbsp;10-K for the fiscal year ended April 30,
2016, filed with the SEC on July 14, 2016.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Outstanding Equity Awards at Fiscal Year-End</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth certain information regarding unexercised stock options held by our Named Executive Officers
as of fiscal year ended April 30, 2016:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; background-color: White">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD COLSPAN="12" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><B>Option Awards</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Named Executive Officer</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><font style="font-size: 10pt"><b>Number of Securities Underlying Unexercised Options (#) Exercisable</b></font></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><font style="font-size: 10pt"><b>Number of Securities Underlying Unexercised Options (#) Unexercisable</b></font></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><font style="font-size: 10pt"><b>Option Exercise Price ($)</b></font></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Option</b></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Expiration</b></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Date</b></P></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 19%; text-align: left">Steven W. King</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 17%; text-align: right">50,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">&ndash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">1.95</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 18%; text-align: center">01/11/2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">221,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">02/01/2020</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">142,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">05/02/2021</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">262,637</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.95</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">02/17/2022</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.46</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">05/04/2022</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12/27/2022</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.41</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">05/06/2023</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.39</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">10/15/2023</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">350,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000 <SUP>(1)</SUP></TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">05/06/2024</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt dashed">112,500</TD><TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt dashed"><font style="font-size: 10pt">187,500 <sup>(2)</sup></font></TD><TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt dashed">1.31</TD><TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt dashed">05/11/2025</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">Paul J. Lytle</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.95</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">01/11/2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">02/01/2020</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">05/02/2021</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.95</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">02/17/2022</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.46</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">05/04/2022</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12/27/2022</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.41</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">05/06/2023</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">175,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">25,000 <SUP>(1)</SUP></FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">05/06/2024</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt dashed">56,250</TD><TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt dashed"><font style="font-size: 10pt">93,750 <sup>(2)</sup></font></TD><TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt dashed">1.31</TD><TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt dashed">05/11/2025</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Shelley P.M. Fussey</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.95</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">01/11/2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">02/01/2020</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">05/02/2021</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.95</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">02/17/2022</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">125,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.46</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">05/04/2022</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12/27/2022</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.41</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">05/06/2023</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">87,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font-size: 10pt">12,500 <sup>(1)</sup></font></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">05/06/2024</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt dashed">28,125</TD><TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt dashed"><font style="font-size: 10pt">46,875 <sup>(2)</sup></font></TD><TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt dashed">1.31</TD><TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt dashed">05/11/2025</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">Joseph S. Shan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">07/06/2017</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.95</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">01/11/2018</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">02/01/2020</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.44</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">05/02/2021</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.95</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">02/17/2022</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.46</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">05/04/2022</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12/27/2022</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.41</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">05/06/2023</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">87,500</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font-size: 10pt">12,500 <sup>(1)</sup></font></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">05/06/2024</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt dashed">37,500</TD><TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt dashed"><font style="font-size: 10pt">62,500 <sup>(2)</sup></font></TD><TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt dashed">1.31</TD><TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt dashed">05/11/2025</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Mark R. Ziebell</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">225,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.47</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">06/20/2022</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">12/27/2022</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">175,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.41</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">05/06/2023</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">153,125</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><font style="font-size: 10pt">21,875 <sup>(1)</sup></font></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">05/06/2024</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt dashed">37,500</TD><TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt dashed"><font style="font-size: 10pt">62,500 <sup>(2)</sup></font></TD><TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt dashed">1.31</TD><TD STYLE="text-align: left; border-bottom: Black 1pt dashed">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt dashed">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt dashed">05/11/2025</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">___________________</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Option vests in eight (8) equal quarterly installments over a two-year period beginning August
6, 2014 and each quarter thereafter until fully-vested.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Option vests in eight (8) equal quarterly installments over a two-year period beginning August
11, 2015 and each quarter thereafter until fully-vested.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Option Exercises and Stock Vested</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no stock
option exercises or vesting of restricted stock by the Company&rsquo;s Named Executive Officers during the fiscal year ended April
30, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview of Employment Agreements and Potential Payments
Upon Termination or Change-in-Control</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Employment Agreements</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into
an employment agreement with each of our Named Executive Officers, each of which are subject to automatic one-year extensions annually
unless either party gives written notice of such party&rsquo;s intent not to renew the employment agreement at least ninety (90)&nbsp;days
prior to the commencement of the next year&rsquo;s period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each employment agreement
provides that the executive officer must devote his or her full business time to the performance of services to the Company. In
addition, each executive officer has agreed to maintain the confidentiality of the Company&rsquo;s proprietary information, and
that all work product discovered or developed by him or her in the course of his or her employment belongs to the Company. Each
executive officer has further agreed that he or she will not (i) compete with the Company, directly or indirectly, during the course
of such executive&rsquo;s employment within the United States or any foreign country in which the Company has done business or
has actually investigated doing business or where its products are sold or distributed, or (ii) solicit Company employees or customers
during the course of employment and for a period of one year following the termination of such executive&rsquo;s employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has the
right to terminate each executive&rsquo;s employment for &ldquo;cause&rdquo; if such executive (a) breaches in any material respect
or fails to fulfill in any material respect his or her fiduciary duty owed to Company; (b) breaches in any material respect his
or her employment agreement or any other confidentiality or non-solicitation, non-competition agreement with the Company; (c) pleads
guilty to or is convicted of a felony; (d) is found to have engaged in any reckless, fraudulent, dishonest or grossly negligent
misconduct, (e) fails to perform his or her duties to the Company, provided that he or she fails to cure any such failure within
thirty (30) days after written notice from Company of such failure, provided further, however, that such right to cure shall not
apply to any repetition of the same failure previously cured under the agreement; or (f) violates any material rule, regulation
or policy of the Company that may be established and made known to Company&rsquo;s employees from time to time, including without
limitation, the Company&rsquo;s employee handbook. If an executive is terminated for &ldquo;cause&rdquo;, he or she shall have
no right to receive any compensation or benefit under his or her employment agreement after such termination other than base salary
and paid time-off earned or accrued but unpaid as of the date of termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following discussion
describes the amounts that we would pay or provide to our Named Executive Officers or, as applicable, their beneficiaries under
these employment agreements as a result of (i) termination without cause or resignation for good reason, (ii) termination following
a change-in-control, (iii) death or disability, and (iv) voluntary resignation with extended notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Payments Upon Termination Without
Cause or Resignation for Good Reason</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we terminate Mr.
King&rsquo;s, Mr. Lytle&rsquo;s or Mr. Ziebell&rsquo;s employment without cause or the executive terminates his employment for
&ldquo;good reason&rdquo;, such executive is entitled to (i) continued base salary and group insurance benefits for a period of
twelve (12) months, and (ii) the payment of any prorated target bonus. In addition, each of Mr. King, Mr. Lytle and Mr. Ziebell
shall have a period of time equal to the lesser of two years following the date of such termination or until the original expiration
date of the applicable option agreement to exercise any vested and outstanding stock options as of the date of such termination.
If we terminate Dr. Fussey&rsquo;s or Mr. Shan&rsquo;s employment without cause or such executive terminates his or her employment
for good reason, such executive shall be entitled to (i) continued base salary and group insurance benefits for a period of twelve
(12) months, and (ii) the payment of any prorated target bonus. In addition, each of Dr. Fussey and Mr. Shan shall have a period
of time equal to the lesser of twelve (12) months following the date of such termination or until the original expiration date
of the applicable option agreement to exercise any vested and outstanding stock options as of the date of such termination. An
executive&rsquo;s receipt of the foregoing severance benefits shall be conditioned upon such executive&rsquo;s execution of a general
release of known and unknown claims in favor of the Company and its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each employment agreement
defines &ldquo;good reason&rdquo; as (a) the Company relocates executive&rsquo;s principal place of work to a location more than
fifty (50) miles from the original location, without the executive&rsquo;s prior written approval; (b)&nbsp;the executive&rsquo;s
position and/or duties are modified so that his or her duties are no longer consistent with the executive&rsquo;s title; or (c)
the executive&rsquo;s annual base salary and related benefits, as adjusted from time to time, are reduced without his or her written
authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth the potential payments to our Named Executive Officers assuming a termination without cause or resignation for good
reason with estimated benefits calculated as if the termination occurred on or about April 30, 2016:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Named Executive Officer</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Base </b></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-size: 10pt"><b>Salary ($)</b></font><b><sup>(1)</sup></b></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-size: 10pt"><b>Target</B></FONT></P>
                                                                                                  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Bonus ($)</b></font><b><sup>(2)</sup></b></P></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Group </b></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><font style="font-size: 10pt"><b>Benefits ($)</b></font><b><sup>(3)</sup></b></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total ($)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 40%; text-align: left">Steven W. King</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 11%; text-align: center">520,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 11%; text-align: center">312,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 11%; text-align: center">34,819</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 11%; text-align: center">866,819</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Paul J. Lytle</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">390,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">156,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">35,398</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">581,398</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Shelley P.M. Fussey</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">321,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">112,350</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">13,988</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">447,338</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Joseph S. Shan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">300,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">105,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">35,280</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">440,280</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Mark R. Ziebell</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">348,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">121,800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">35,344</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">505,144</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">________________</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Represents payment of base salary for a period of twelve (12) months.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">The payment of a Target Bonus to the Named Executive Officers is at the sole discretion of the
Company&rsquo;s Board of Directors. Amount includes the maximum proposed Target Bonus as a percentage of base salary established
for the fiscal year ended April 30, 2016 for each Named Executive Officer as follows: Mr. King &ndash; 60%; Mr. Lytle &ndash; 40%;
Mr. Ziebell &ndash; 35%; Dr. Fussey &ndash; 35%; and Mr. Shan &ndash; 35%.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">Represents estimated payment to reimburse executive&rsquo;s monthly benefits premiums for continued
group health, dental, and vision benefits in addition to premiums for disability and term life insurance during the severance period
of twelve (12) months. Amounts were calculated based on current premiums paid for executive&rsquo;s benefits.</TD></TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Payments Upon a Termination in
Connection with a Change-in-Control</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of a change-in-control
of Peregrine, if a Named Executive Officer&rsquo;s (i) employment is terminated other than for cause within three (3) months prior
or thirty-six (36) months following a change-in-control (in the case of Mr. King) or twenty-four (24) months following a change-in-control
(in the case of the other Named Executive Officers), or (ii) such executive terminates his employment for &ldquo;good reason&rdquo;
within twelve (12) months following a change-in-control, the executive shall be paid a lump sum amount equal to (a) thirty-six
(36) months&rsquo;, in the case of Mr. King, and twenty-four (24) months&rsquo;, in the case of the other Named Executive Officers,
base salary then in effect, (b) one hundred percent (100%) of such executive&rsquo;s target bonus, and (c) payment of group insurance
benefits for thirty-six (36) months, in the case of Mr. King, and twenty-four (24) months, in the case of the other Named Executive
Officers. In addition, each of the Named Executive Officers&rsquo; outstanding unvested stock options immediately shall become
fully vested and each shall have a period of time equal to the lesser of two years following the date of such termination or until
the original expiration date of the applicable option agreement to exercise any vested and outstanding stock options as of the
date of such termination. An executive&rsquo;s receipt of the foregoing severance benefits shall be conditioned upon such executive&rsquo;s
execution of a general release of known and unknown claims in favor of the Company and its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth the potential payments to our Named Executive Officers assuming a termination without cause or resignation for good
reason in connection with a change-in-control, with estimated benefits calculated assuming the change-in-control and termination
of employment occurred on or about April 30, 2016:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; background-color: White">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Named </b></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Executive Officer</b></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><font style="font-size: 10pt"><b>Base Salary($)</b></font><b><sup>(1)</sup></b></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><font style="font-size: 10pt"><b>Target Bonus ($)</b></font><b><sup>(2)</sup></b></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><font style="font-size: 10pt"><b>Stock Option Acceleration ($)</b></font><b><sup>(3)</sup></b></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><font style="font-size: 10pt"><b>Group Benefits ($)</b></font><b><sup>(4)</sup></b></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total ($)</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 35%; text-align: left">Steven W. King</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,560,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">312,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: center">&ndash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 9%">104,458</TD>
    <TD STYLE="width: 1%">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 9%">1,976,458</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Paul J. Lytle</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">780,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">156,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">70,796</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">1,006,796</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Shelley P.M. Fussey</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">642,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">112,350</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">27,977</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">782,327</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Joseph S. Shan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">600,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">105,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">70,561</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">775,561</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Mark R. Ziebell</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">696,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">121,800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: right">70,688</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">888,488</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">______________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents payment of base salary for a period of thirty-six (36) months for Mr. King and twenty-four (24) months for Mr. Lytle, Dr. Fussey, Mr. Shan and Mr. Ziebell.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The payment of a Target Bonus to the Named Executive Officer is at the discretion of the Company&rsquo;s Board of Directors. A Target Bonus is equal to a percentage of the Named Executive Officer&rsquo;s annual base salary as follows: Mr. King &ndash; 60%; Mr. Lytle &ndash; 40%; Dr. Fussey &ndash; 35%; Mr. Shan &ndash; 35%; and Mr. Ziebell &ndash; 35%. The above assumes that the Board of Directors authorized the payment of the full Target Bonus to each executive for the fiscal year.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount calculated by multiplying the number of unvested shares subject to accelerated vesting under outstanding stock options by the difference between $0.3541 (the closing price per share of our common stock on the last trading day of fiscal year ended April 30, 2016) and the exercise price per share of the underlying stock option in connection with a change-in-control event. These amounts, if any, do not correspond to the actual value that may be recognized by each Named Executive Officer as there can be no assurance that the options will ever be exercised or that the value on exercise will be equal to the amounts shown in this column.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents estimated payment to reimburse executive&rsquo;s monthly benefits premiums for continued group health, dental, and vision benefits in addition to premiums for disability and term life insurance during the severance period of thirty-six (36) months for Mr. King and twenty-four (24) months for Mr. Lytle, Dr. Fussey, Mr. Shan and Mr. Ziebell. Amounts were calculated based on current premiums paid for executive&rsquo;s benefits.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Payments upon Death or Disability</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of the
death or disability, as defined in the employment agreements, of a Named Executive Officer, the Company will not pay any further
compensation or benefits after such event other than the payment by the Company of group insurance benefits previously provided
to our Named Executive Officers for a period of twelve (12) months, in the case of Mr. King, Mr. Lytle and Mr. Ziebell, and nine
(9) months, in the case of Dr. Fussey and Mr. Shan. Amounts were calculated based on current premiums paid for executive&rsquo;s
benefits as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Named Executive Officer</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Group Benefits ($)</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 33%; text-align: left">Steven W. King</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">34,819</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Paul J. Lytle</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,398</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Shelley P.M. Fussey</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,491</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Joseph S. Shan</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,460</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Mark R. Ziebell</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,344</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Payments upon Executive&rsquo;s
Voluntary Resignation with Extended Notice Period</B></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that a
Named Executive Officer voluntarily resigns, and in connection therewith provides ninety (90) days&rsquo; advance written notice
(the &ldquo;Extended Notice Period&rdquo;) to the Company, and provided the executive shall have been employed by the Company for
a period of at least five (5) years (in the case of Dr. Fussey, Mr. Shan and Mr. Ziebell), the Company will pay the Named Executive
Officer&rsquo;s base salary then in effect and shall continue to provide other contractual benefits including group insurance benefits
during the Extended Notice Period and for a period of nine (9) months in the case of Mr. King and six (6) months in the case of
the other Named Executive Officers after the Extended Notice Period provided the executive makes themselves telephonically available
to the Board of Directors and the Company&rsquo;s executive team for up to two (2) hours per week.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Compensation Committee Interlocks and Insider Participation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following non-employee
directors currently serve on the Compensation Committee of the Board of Directors: Mr. Carlton M. Johnson, Jr., Mr. David H. Pohl
and Mr. Eric S. Swartz. There are no interlocks of executive officers or directors of the Company serving on the compensation committee
or equivalent committee of another entity, which has any director or executive officer serving on the Compensation Committee, other
committees or the Board of Directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certain Relationships and Related Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except for the compensation
arrangements between us and our executive officers and directors described above under &ldquo;Compensation Discussion and Analysis,&rdquo;
since May 1, 2015, we have not been a party to any transactions involving more than $120,000 and in which any director, nominee
for director, executive officer, holder of more than 5% of our common stock or any immediate family member of the foregoing has
a direct or indirect material interest, nor are any such transactions currently proposed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Audit Committee&rsquo;s
charter requires that it review and approve any related-party and conflicts of interest transactions. In considering related-party
transactions, the Audit Committee would consider the relevant available facts and circumstances, including, but not limited to,
(i) the risks, costs and benefits to us, (ii) the impact on a director&rsquo;s independence in the event the related party is a
director, immediate family member of a director or an entity with which a director is affiliated, (iii) the terms of the transaction,
(iv) the availability of other sources for comparable services or products, and (v) the terms available to or from, as the case
may be, unrelated third parties or to or from employees generally. In the event a director has an interest in the proposed transaction,
the director must recuse himself or herself from the deliberations and approval. In determining whether to approve, ratify or reject
a related-party transaction, the Audit Committee evaluates whether, in light of known circumstances, the transaction is in, or
is inconsistent with, our best interests and those of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: blue; border-top: Black 0.5pt solid; border-bottom: Black 0.5pt solid"><FONT STYLE="font-variant: small-caps; color: White"><B>Compensation
Committee Report</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The Report of the
Compensation Committee of the Board of Directors shall not be deemed incorporated by reference by any general statement incorporating
by reference this Proxy Statement into any filing under the Securities Act or under the Exchange Act, except to the extent that
the Company specifically incorporates this information by reference, and shall not otherwise be deemed filed under such Acts. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Committee
of our Company has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K with
management and, based on such review and discussions, the Compensation Committee recommended to the Board of Directors that the
Compensation Discussion and Analysis be included in this Proxy Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Compensation Committee of the Board of Directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Eric S. Swartz (Chairman)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Carlton M. Johnson, Jr.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David H. Pohl</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Equity Compensation Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently maintain
six equity compensation plans: the 2002 Stock Incentive Plan (the &ldquo;2002 Plan&rdquo;), the 2003 Stock Incentive Plan (the
&ldquo;2003 Plan&rdquo;), the 2005 Stock Incentive Plan (the &ldquo;2005 Plan&rdquo;), the 2009 Stock Incentive Plan (the &ldquo;2009
Plan&rdquo;), the 2010 Stock Incentive Plan (the &ldquo;2010 Plan&rdquo;) and the 2011 Stock Incentive Plan, as amended on October
15, 2015 (the &ldquo;2011 Plan&rdquo;), in addition to which we maintain our Employee Stock Purchase Plan. The 2003 Plan, 2005
Plan, 2009 Plan, 2010 Plan and 2011 Plan, as well as the Employee Stock Purchase Plan, were approved by our stockholders, while
we did not submit the 2002 Plan for stockholder approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The 2002 Plan, which
expired in June 2012, was a broad-based non-qualified stock option plan for the issuance of up to 600,000 options. The 2002 Plan
provided for the granting of options to purchase shares of our common stock at prices not less than the fair market value of our
common stock at the date of grant and generally expired ten years after the date of grant. No additional options can be granted
under the expired 2002 Plan, however, the terms of the 2002 Plan remain in effect with respect to outstanding options granted under
the 2002 Plan until they are exercised, canceled or expired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table
sets forth certain information as of April 30, 2016 concerning our common stock that may be issued upon the exercise of options
or pursuant to purchases of stock under all of our equity compensation plans approved by stockholders and equity compensation plans
not approved by stockholders in effect as of April 30, 2016:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Plan Category</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(a)</b></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Number&nbsp;of&nbsp;Securities to be Issued Upon the Exercise of Outstanding Options, Warrants and Rights</b></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(b)</b></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights ($/share)</b></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(c)</b></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Number of Shares Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a))</b></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 28%; text-align: left; padding-left: 11pt; text-indent: -11pt">Equity compensation plans approved by stockholders</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 20%; text-align: center">23,520,815</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 20%; text-align: center">1.48</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 20%; text-align: center">15,809,904</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 11pt; text-indent: -11pt">Equity compensation plans not approved by stockholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">230,446 <sup>(1)</sup></P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">2.07</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&ndash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -11pt; padding-left: 11pt">Employee Stock Purchase Plan approved by stockholders</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">&ndash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: center">1,408,659</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: center"><font style="font-size: 10pt">23,751,261 <sup>(2)</sup></font></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: center"><font style="font-size: 10pt">1.48 <sup>(3)</sup></font></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: center">17,218,563</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">______________</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Includes an aggregate of 35,908 options granted in a previous fiscal year to one of our Named Executive
Officers.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Represents shares to be issued upon the exercise of outstanding options. There were no shares of
common stock subject to restricted stock awards as of April 30, 2016.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">Represents the weighted-average exercise price of outstanding options.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: blue; border-top: Black 0.5pt solid; border-bottom: Black 0.5pt solid"><FONT STYLE="font-variant: small-caps; color: White"><B>Other
Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Stockholder Proposals for 2017 Annual Meeting of Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stockholder proposals
may be included in our proxy materials for an Annual Meeting so long as they are provided to us on a timely basis and satisfy the
other conditions set forth in applicable SEC rules. For a stockholder proposal to be included in our proxy materials for the 2017
Annual Meeting of Stockholders, the proposal must be received at our principal executive offices at 14282 Franklin Avenue, Tustin,
California 92780, addressed to the Secretary, not later than May 5, 2017, and must comply with all applicable requirements of Rule
14a-8 promulgated under the Exchange Act. However, if our 2017 Annual Meeting of Stockholders is not held between September 13,
2017 and November 12, 2017, then the deadline will be a reasonable time prior to the time we begin to print and send our proxy
materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stockholder business
that is not intended for inclusion in our proxy materials may be brought before the 2017 Annual Meeting so long as we receive notice
of the proposal as specified by our Bylaws, addressed to the Secretary at our principal executive offices at 14282 Franklin Avenue,
Tustin, California 92780, by not earlier than the close of business on June 15, 2017 and not later than the close of business on
July 15, 2017. However, if the 2017 Annual Meeting of Stockholders is not held between September 13, 2017 and November 12, 2017,
the notice must be delivered no earlier than the close of business on the 120th day nor later than the close of business on the
90th day prior to the 2017 Annual Meeting of Stockholders or, if later, the 10th day following the day on which public disclosure
of the date of the 2017 Annual Meeting of Stockholders is made. All such notices must be submitted in accordance with the specific
procedural requirements in our Bylaws and must include certain information with regard to the person submitting the proposal. Failure
to comply with our Bylaw procedures and deadlines may preclude presentation of the proposal at our 2017 Annual Meeting of Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other Matters</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the date of this
Proxy Statement, the Board of Directors knows of no other business that will be conducted at the Annual Meeting other than as described
in this Proxy Statement. If any other matter or matters are properly brought before the Annual Meeting, or any adjournment or postponement
of the Annual Meeting, it is the intention of the persons named in the accompanying form of proxy to vote the proxy on such matters
in accordance with their best judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Annual Report on Form 10-K</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of the Company&rsquo;s
Annual Report on Form 10-K, as filed with the SEC (exclusive of Exhibits), will be furnished by first class mail, within one business
day of receipt of request, without charge to any person from whom the accompanying proxy is solicited upon written request to Peregrine
Pharmaceuticals, Inc., Attention: Corporate Secretary, 14282 Franklin Avenue, Tustin, California 92780. If Exhibit copies are requested,
a copying charge of $.20 per page will be made. In addition, all of the Company&rsquo;s public filings, including the Annual Report
on Form 10-K, can be found on our website at www.peregrineinc.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">By Order of the Board of Directors</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD><B><I><IMG SRC="image_004.jpg" ALT="" STYLE="width: 144px; height: 51px"></I></B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><I>&nbsp;</I></TD>
    <TD><I>Mark R. Ziebell</I></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><I>&nbsp;</I></TD>
    <TD><I>Vice President, General Counsel and <BR>
Corporate Secretary</I></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">August 26, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><I><U>Exhibit A</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATE OF AMENDMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATE OF INCORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PEREGRINE PHARMACEUTICALS, INC.,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>A DELAWARE CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">PEREGRINE PHARMACEUTICALS,
INC., a Delaware corporation organized and existing under and by virtue of the Delaware General Corporation Law (hereinafter referred
to as the &ldquo;Corporation&rdquo;), hereby certifies as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1. That at a meeting
of the Board of Directors of the Corporation resolutions were duly adopted setting forth a proposed amendment of the Certificate
of Incorporation of the Corporation, declaring said amendment to be advisable and directing said amendment to be submitted to the
stockholders of the Corporation at a special meeting. The resolutions setting forth the proposed amendment is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;RESOLVED, that ARTICLE 4 of the Certificate
of Incorporation be amended by adding the following paragraph at the end thereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 49.5pt; text-align: justify">&ldquo;Effective as of the
close of business on the filing date of this Certificate of Amendment with the Secretary of State of the State of Delaware (the
&ldquo;Effective Time&rdquo;), every [insert number ranging up to seven] outstanding shares of Common Stock, par value $0.001,
of the Corporation issued and outstanding or held in the treasury of the Corporation as of the close of business on ________ __,
20__ will automatically be combined, reclassified and changed into one (1) fully paid and non-assessable share of Common Stock,
par value $0.001, without any further action by the holders of such shares; provided, however, that if such reclassification results
in any stockholder being entitled to fractional shares that when aggregated equal less than a whole share of Common Stock such
fractional shares shall be reclassified and converted from and after the Effective Time into one whole share of Common Stock in
lieu of such fractional shares. No other exchange, reclassification or cancellation of issued shares shall be effected by this
Amendment.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in 0pt 49.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2. That thereafter,
pursuant to resolution of the Board of Directors, an Annual Meeting of the stockholders of the Corporation was duly called and
held, upon notice in accordance with Section 222 of the Delaware General Corporation Law, at which Annual Meeting the necessary
number of shares as required by statute were voted in favor of the amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3. That said amendment
was duly adopted in accordance with the provisions of Section 242 of the Delaware General Corporation Law of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
the Corporation has caused this Certificate of Amendment to be executed by Steven W. King, its President &amp; CEO, and attested
to by Mark R. Ziebell, its Corporate Secretary, this [__] day of [________], [____].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">PEREGRINE PHARMACEUTICALS, INC.,</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>a Delaware corporation</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>By:________________________________</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>Steven W. King, President &amp; CEO</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ATTEST:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">__________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mark R. Ziebell, Corporate Secretary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><I><U>Exhibit B</U></I></B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">AMENDMENT TO THE<BR>
PEREGRINE PHARMACEUTICALS, INC.<BR>
2010 EMPLOYEE STOCK PURCHASE PLAN</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Peregrine Pharmaceuticals,
Inc., a Delaware corporation (the &ldquo;Company&rdquo;), previously established the Peregrine Pharmaceuticals, Inc. 2010 Employee
<FONT STYLE="font-family: Times New Roman, Times, Serif">Stock Purchase Plan, as amended </FONT>(the &ldquo;Plan&rdquo;). The Plan
was approved by the Company&rsquo;s stockholders at the Company&rsquo;s 2010 Annual Meeting of Stockholders. By adoption of this
instrument, the Company desires to amend the Plan to increase the total number of shares of common stock available for grant
under the Plan by 10,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>This Amendment shall be effective as of the date on which it is approved by the Company&rsquo;s stockholders at the Company&rsquo;s
2016 Annual Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Section 5.1 (<U>Shares Subject to the Plan &ndash; Number of Shares</U>) of the Plan is hereby amended and restated in its
entirety to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">5.1<I>&#9;</I><B><U>Number of
Shares</U>.</B> Subject to adjustment provided in Article 11, the aggregate number of Shares reserved and available for delivery
under this Plan shall be fifteen million (15,000,000). If any Option granted under this Plan shall for any reason terminate without
having been exercised, the Shares not purchased under such Option shall again be available for issuance under this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>This Amendment shall supersede the provisions of the Plan to the extent those provisions are inconsistent with the provisions
and intent of this Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
the Company has caused this Amendment to be executed as of this _____ day of __________________, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>The Company:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">PEREGRINE PHARMACEUTICALS,
INC.</FONT><BR>
a Delaware corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:<U>___________________________________</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Title:</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%; padding-left: 10pt"><IMG SRC="image_006.jpg" ALT=""><BR>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 1.5pt 0 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><B><I>PEREGRINE
PHARMACEUTICALS, INC.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 1.5pt 0 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><B><I>C/O
BROADRIDGE</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 1.5pt 0 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><B><I>P.O.
BOX 1342</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 1.5pt 0 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt"><B><I>BRENTWOOD,
NY 11717</I></B></FONT></P>


&nbsp;</TD>
    <TD STYLE="width: 17%">&nbsp;</TD>
    <TD STYLE="width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>VOTE
                           BY INTERNET - www.proxyvote.com</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">Use
the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 P.M. Eastern Time
the day before the cut-off date or meeting date. Have your proxy card in hand when you access the web site and follow the instructions
to obtain your records and to create an electronic voting instruction form.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt"><B>ELECTRONIC
DELIVERY OF FUTURE PROXY MATERIALS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">If
you would like to reduce the costs incurred by our company in mailing proxy materials, you can consent to receiving all future
proxy statements, proxy cards and annual reports electronically via e-mail or the Internet. To sign up for electronic delivery,
please follow the instructions above to vote using the Internet and, when prompted, indicate that you agree to receive or access
proxy materials electronically in future years.</FONT><BR>
<BR>
 <FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>VOTE BY PHONE - 1-800-690-6903</B></FONT> <FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><BR>
Use any touch-tone telephone to transmit your voting instructions up until 11:59 P.M. Eastern Time the day before the cut-off date or meeting date. Have your proxy card in hand when you call and then follow the instructions.</font><BR>
</P>
<BR>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif"><B>VOTE
        BY MAIL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 8pt Arial, Helvetica, Sans-Serif">Mark,
sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o
Broadridge, 51 Mercedes Way, Edgewood, NY 11717.</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">TO
VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:</FONT></P>

<P STYLE="margin-top: 0; text-align: right; margin-bottom: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">E13162-P82106&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;KEEP
THIS PORTION FOR YOUR RECORDS</FONT></P>

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt dashed; width: 100%"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: right; margin-bottom: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 7pt">DETACH
AND RETURN THIS PORTION ONLY</FONT></P>

<P STYLE="margin-top: 0; text-align: right; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>THIS
PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;<IMG SRC="pxycard-1.jpg" ALT=""></P>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 5%; border-right: Black 1pt solid"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 90%; border-top: Black 1pt solid; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>
                                                        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">Bring
                                         this admission ticket with you to the meeting on October 13, 2016. Do not mail.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">This
admission ticket admits you to the meeting. You will not be let into the meeting without an admission</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">ticket
or other proof of stock ownership as of August 19, 2016, the record date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>ADMISSION
TICKET</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>PEREGRINE
PHARMACEUTICALS, INC. </B><BR>
2016 Annual Meeting of Stockholders</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">October
13, 2016<BR>
10:00 a.m. Pacific Daylight Time<BR>
Avenue of the Arts Hotel<BR>
3350 Avenue of the Arts<BR>
Costa Mesa, California 92626</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Important
Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>to
be Held on October 13, 2016:</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">The
proxy statement and 2016 annual report to stockholders are available at <FONT STYLE="font-size: 10pt; color: blue"><U>www.proxyvote.com</U>.
</FONT></FONT></P>
<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>
<P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>



</TD>
    <TD STYLE="width: 5%; border-left: Black 1pt solid"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt dashed; width: 100%"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.15pt 0 4.15pt; text-align: right"><FONT STYLE="font: 7pt Arial, Helvetica, Sans-Serif">E13163-P82106</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>



<P STYLE="margin: 0"></P>

<DIV STYLE="margin: 0.1in; padding: 0.1in; border: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>PEREGRINE
PHARMACEUTICALS, INC.</B><BR>
This Proxy is Solicited on Behalf of the Board of Directors <BR>
For the 2016 Annual Meeting of Stockholders <BR>
To Be Held Thursday, October 13, 2016, at 10:00 a.m. PDT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">The
undersigned hereby appoints Steven W. King and Paul J. Lytle, or any one or all of them, with full power of substitution, attorneys
and proxies to represent the undersigned at the annual meeting of stockholders of PEREGRINE PHARMACEUTICALS, INC. to be held on
October 13, 2016 and at any adjournment or postponement thereof, with all the power which the undersigned would possess if personally
present and to vote, as specified on the reverse side, all shares of Common Stock which the undersigned may be entitled to vote
at said meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">IF
NO OTHER INDICATION IS MADE ON THE REVERSE SIDE OF THIS FORM, THIS PROXY WILL BE VOTED <B><U>FOR ALL</U></B> NOMINEES FOR DIRECTOR
LISTED IN ITEM 1, AND <B><U>FOR</U></B> ITEMS 2, 3, 4 AND 5 AS MORE SPECIFICALLY DESCRIBED IN THE PROXY STATEMENT AND IN THE DISCRETION
OF THE PERSONS NAMED ABOVE IN ANY OTHER MATTER WHICH MAY PROPERLY COME BEFORE THE ANNUAL MEETING. IF SPECIFIC INSTRUCTIONS ARE
INDICATED, THIS PROXY WILL BE VOTED IN ACCORDANCE WITH THOSE INSTRUCTIONS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">YOU MAY
REVOKE THIS PROXY AT ANY TIME PRIOR TO THE VOTE AT THE ANNUAL MEETING.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">PLEASE COMPLETE, DATE AND SIGN THIS PROXY AND RETURN
IT IN THE ACCOMPANYING ENVELOPE.</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>



<P STYLE="margin: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 85%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 100%; border: Black 1pt solid"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 6pt; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Address
                                         Changes/Comments:</B>_________________________________</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 5.4pt; text-align: center; margin-bottom: 5.4pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;&nbsp;_________________________________________________________&nbsp;&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>

</TD></TR>
</TABLE>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 4.2pt 6.5pt 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 8pt">(If
you noted any Address Changes/Comments above, please mark corresponding box on the reverse side.</FONT><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">)</FONT></P>



<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 6pt; text-align: left"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>Continued
                                         and to be signed on reverse side</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif"><B>&nbsp;</B></FONT></P>

</DIV>


<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif">&nbsp;</FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
